var title_f15_5_15440="Battery schematic";
var content_f15_5_15440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Button battery schematic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic demonstrates the common design of a button battery including the seal/crimp area, anode, cathode, and electrolyte-soaked separator which usually consists of potassium or sodium hydroxide solution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kelly Sinclair, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15440=[""].join("\n");
var outline_f15_5_15440=null;
var title_f15_5_15441="Chest XRay bronchogenic cyst";
var content_f15_5_15441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior-posterior and lateral views demonstrate a cystic lesion in the left upper lobe. There is an air-fluid level present, suggesting prior or current infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15441=[""].join("\n");
var outline_f15_5_15441=null;
var title_f15_5_15442="Port placement for laparoscopic appendectomy";
var content_f15_5_15442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Port placement for laparoscopic appendectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through the umbilical port and two additional 5 mm ports are placed. The first is placed lateral to the left rectus muscle and medial to the anterior superior iliac spine. The second is placed in the suprapubic region at least 2 finger breadths superior to the pubic tubercle. Both the surgeon and the assistant stand on the patient's left side.",
"    <br>",
"     The surgeon operates using the two 5 mm ports (shown in red) and the assistant operates the laparoscope (shown in blue). One 12 mm port is needed to pass a surgical stapler to transect the appendix. The appendix is removed through the periumbilical port site, in a specimen bag.",
"     <div class=\"footnotes\">",
"      * Port placement and technique may vary amongst laparoscopic surgeons.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15442=[""].join("\n");
var outline_f15_5_15442=null;
var title_f15_5_15443="Sweat bee";
var content_f15_5_15443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sweat bee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15443=[""].join("\n");
var outline_f15_5_15443=null;
var title_f15_5_15444="Carfilzomib: Patient drug information";
var content_f15_5_15444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carfilzomib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=see_link\">",
"     see \"Carfilzomib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14791719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kyprolis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14787732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multiple myeloma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14787731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3859182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carfilzomib.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14787736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14787737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14787799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14787734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14787738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86238 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15444=[""].join("\n");
var outline_f15_5_15444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14791719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787732\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787731\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787736\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787737\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787799\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787734\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787738\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/24/13702?source=related_link\">",
"      Carfilzomib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_5_15445="Primidone: Patient drug information";
var content_f15_5_15445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Primidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=see_link\">",
"     see \"Primidone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/11/42167?source=see_link\">",
"     see \"Primidone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mysoline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Primidone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control tremors.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to primidone, phenobarbital, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10993 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15445=[""].join("\n");
var outline_f15_5_15445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021680\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021682\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021681\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021686\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021687\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021689\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021684\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021685\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021690\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021691\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30952?source=related_link\">",
"      Primidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/11/42167?source=related_link\">",
"      Primidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_5_15446="Anomalies of the urachus";
var content_f15_5_15446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anomalies of the urachus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 528px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15446=[""].join("\n");
var outline_f15_5_15446=null;
var title_f15_5_15447="UV lesions I";
var content_f15_5_15447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66203%7EALLRG%2F54877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66203%7EALLRG%2F54877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular patch with elevated borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticarial patch with central ecchymosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15447=[""].join("\n");
var outline_f15_5_15447=null;
var title_f15_5_15448="Complications of transjugular intrahepatic portosystemic shunts";
var content_f15_5_15448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of transjugular intrahepatic portosystemic shunts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Jasmohan S Bajaj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15448/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/5/15448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transjugular intrahepatic portosystemic shunt or stent-shunt (TIPS) insertion is an important addition to the therapeutic armamentarium against portal hypertension; it decompresses the portal vein in a manner analogous to side-to-side surgical portacaval shunts but avoids the risks of general anesthesia and major surgery. TIPS insertion involves creation of a low-resistance channel between the hepatic vein and the intrahepatic portion of the portal vein (usually the right branch) using angiographic techniques (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). The tract is kept patent by deployment of an expandable metal stent across it, thereby allowing blood to return to the systemic circulation. TIPS insertion has been used primarily for control of variceal bleeding, but also appears to be effective in refractory ascites (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, TIPS insertion can be associated with a number of complications, some of which may be fatal. It is therefore essential for all who use this procedure to be cognizant of the clinical spectrum of TIPS-related complications and their management.",
"   </p>",
"   <p>",
"    The direct procedure-related mortality ranges from 0 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ], and the 30-day mortality ranges from 7 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three broad categories of complications associated with TIPS insertion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Technical complications",
"     </li>",
"     <li>",
"      Complications related to creation of the portosystemic shunt",
"     </li>",
"     <li>",
"      Unique TIPS-related complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the complications related to TIPS insertion. Indications for TIPS insertion, including its use in variceal hemorrhage, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link\">",
"     \"Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical complications associated with TIPS insertion can occur at various stages of the procedure. A needle catheter (Colapinto catheter) is passed via a transjugular route into the hepatic vein and wedged there. The needle is then extruded and advanced through the liver parenchyma to the intrahepatic portion of the portal vein (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complications related to access to the hepatic vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for complications begins from the time procedural sedation is given to the patient. Beside inadvertent carotid artery or tracheal puncture, the most important complication during this part of the procedure is the development of cardiac arrhythmias as the catheter is passed through the heart. This is most likely to occur if the catheter buckles within the right atrium and rubs against its wall or prolapses into the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ]. Although atrial premature beats have little clinical significance, more serious arrhythmias, such as atrial fibrillation, conduction defects (nodal or infranodal), and ventricular tachycardia, can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, in patients with a preexisting left bundle branch block, it is possible that a procedure-related transient right bundle branch block could result in a potentially fatal complete heart block.",
"   </p>",
"   <p>",
"    The likelihood of such arrhythmias may be minimized by correction of electrolyte and acid-base abnormalities prior to the procedure and also by using a Check Flow II (Ring Transjugular Intrahepatic Access set, Cook) introducer. This introducer is a 40 cm, relatively stiff sheath which prevents buckling of the catheter in the right heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complications related to creation of the intrahepatic tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal risk associated with creation of the intrahepatic tract is traversal of the liver capsule during attempts to enter the portal vein. The reported incidence of capsule traversal is approximately 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ]; however, the development of clinically obvious hemoperitoneum is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/2\">",
"     2",
"    </a>",
"    ]. This complication is most likely to occur in two settings: when the liver is small, hard, and displaced upward by tense ascites, thereby making the angle necessary to enter the portal vein from the hepatic vein very acute; and when the portal vein is thrombosed and replaced by collaterals. When the capsule is traversed, anecdotal reports of prevention of bleeding by embolization of the tract with a pledget of gel foam have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TIPS insertion may be facilitated by a large volume paracentesis and careful evaluation of portal vein patency by Doppler sonography prior to the procedure. In addition, if the portal vein is not entered easily, a more complete diagnostic evaluation of portal vein patency by mesenteric angiography should be performed instead of persisting with blind attempts to enter the portal vein.",
"   </p>",
"   <p>",
"    Another important complication during this part of the procedure is the creation of a tract between the shunt or the portal vein and the hepatic artery or bile ducts. The clinical consequences depend upon the specific structures involved. As an example, the inadvertent creation of a TIPS-biliary fistula can cause hemobilia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5\">",
"     5",
"    </a>",
"    ]. Fistulae between both large and microscopic bile ducts and the TIPS lumen have been associated with the development of shunt thrombosis and early stent occlusion (",
"    <a class=\"graphic graphic_picture graphicRef77747 \" href=\"UTD.htm?39/22/40302\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complications of portal vein manipulation and stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare but often fatal complication of TIPS insertion is extrahepatic puncture of the portal vein with exsanguinating hemorrhage after attempts to dilate the site of portal vein puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of this complication can be minimized by avoiding the main portal vein and only using its main branches for stent placement. There are anecdotal reports of successful management by quickly placing a Wallstent across the site of puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive thrombosis of the TIPS, portal vein, or splenic vein occurs in 3 to 12 percent of patients after TIPS insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/1,5,8-10\">",
"     1,5,8-10",
"    </a>",
"    ]. No data exist to clearly implicate preoperative platelet counts, prothrombin time, or procedure time as risk factors for the development of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5\">",
"     5",
"    </a>",
"    ]. Nevertheless, all of the above may contribute in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3993?source=see_link\">",
"     \"Extrahepatic portal vein obstruction (portal vein thrombosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two small studies have evaluated the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and phenprocoumon in preventing stent thrombosis. There was greater patency in patients receiving phenprocoumon but these data are questionable because of a high rate of thrombosis in the control arm. Furthermore, with the introduction of covered stents, TIPS patency has been vastly improved. As a result, anticoagulation is not routinely required after TIPS insertion to maintain shunt patency.",
"   </p>",
"   <p>",
"    When thrombosis occurs, it is accurately detected by Doppler sonography within the first month after TIPS. Once thrombosis occurs, treatment options include thrombolysis, anticoagulation, or suction thrombectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/11\">",
"     11",
"    </a>",
"    ]. In those who are transplant candidates, liver transplantation is the optimal definitive treatment. We have used both suction thrombectomy followed by urgent liver transplant and thrombolysis followed by long-term anticoagulation in this setting. The choice of a specific method depends upon the expertise available and the individual clinical circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPLICATIONS RELATED TO PORTOSYSTEMIC SHUNTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary complication due to shunting of blood from the portal to systemic circulation is the development of portosystemic encephalopathy (PSE). The incidence of PSE following TIPS is approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12-15\">",
"     12-15",
"    </a>",
"    ] and is similar to that reported after surgical portal diversion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one study, for example, 9 of 30 patients receiving TIPS had 24 episodes of PSE during follow-up; in comparison, only six episodes of PSE occurred in 25 concurrent controls treated only with sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12\">",
"     12",
"    </a>",
"    ]. Increasing age, advanced liver failure, and a history of encephalopathy prior to TIPS placement have all been associated with an increased risk of developing PSE after TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12,14,18,19\">",
"     12,14,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diameter of the shunt may influence the development of PSE [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/20\">",
"     20",
"    </a>",
"    ]. According to Poiseuille's equation, resistance to flow can be defined as:",
"   </p>",
"   <p>",
"    &nbsp;Resistance = 8nl &divide; &pi;r(4)",
"   </p>",
"   <p>",
"    where r is the radius of the stent, n is the coefficient of viscosity, and l is the length of the vessel.",
"   </p>",
"   <p>",
"    Thus, the resistance to flow through the shunt decreases exponentially with increasing shunt diameter, resulting in increases in shunt flow and portosystemic shunting. The probability of PSE increases dramatically at shunt diameters above 10 mm. However, one randomized trial that assigned 45 patients to receive either 8 or 10 mm diameter stents failed to show an increased incidence of PSE in the patients with larger diameter shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/21\">",
"     21",
"    </a>",
"    ]. At one year, the probability of being free of PSE was 43 percent in the 8 mm stent arm and 47 percent in the 10 mm stent arm. In addition, the trial was stopped prior to enrolling its goal of 114 patients because of a significantly higher portosystemic pressure gradient in patients who received the smaller shunts (8.9 versus 6.5 mmHg). This correlated with a decrease in the probability of remaining free from complications due to portal hypertension at one year in the 8 mm group compared with the 10 mm group (42 versus 83 percent).",
"   </p>",
"   <p>",
"    Portosystemic encephalopathy usually becomes clinically apparent two to three weeks after TIPS insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The occurrence of PSE six weeks or more after TIPS insertion is usually associated with gastrointestinal bleeding. Pharmacologic prophylaxis with lactitol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    during the first month after TIPS was not beneficial in a controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presenting symptoms of PSE typically include altered sleep pattern, confusion, disorientation, and hepatic coma. The serum ammonia levels are invariably elevated although the precise levels do not correlate well with the degree of mental status changes. Encephalopathy is often precipitated by constipation, dehydration, infections, dietary indiscretion, or electrolyte abnormalities (such as hypokalemia and metabolic alkalosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Theoretically, patients undergoing TIPS insertion should also be susceptible to development of focal neurologic deficits compatible with hepatic myelopathy (also referred to as portosystemic or shunt myelopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Hepatic myelopathy is characterized by paresis of the extremities, muscle spasticity, and the presence of a Babinski sign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H11228107#H11228107\">",
"     \"The detailed neurologic examination in adults\", section on 'Plantar response'",
"    </a>",
"    .) This author has seen one patient who developed a classic case of hepatic myelopathy three years after TIPS placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H23#H23\">",
"     \"Disorders affecting the spinal cord\", section on 'Hepatic myelopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, an attempt was made to quantify in a semi-objective manner the degree of encephalopathy after TIPS using a portosystemic encephalopathy index [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12\">",
"     12",
"    </a>",
"    ]. The PSE index rose sharply within 7 to 10 days after TIPS placement (",
"    <a class=\"graphic graphic_figure graphicRef72160 \" href=\"UTD.htm?7/26/7598\">",
"     figure 2",
"    </a>",
"    ). Over time, the PSE index declined, but at six months, it remained significantly higher than baseline values and values in concurrent matched controls who underwent sclerotherapy. The decline in PSE index may be attributed to both treatment of the encephalopathy and the development of stent stenosis, due to pseudointimal hyperplasia, which reduced the degree of portosystemic shunting.",
"   </p>",
"   <p>",
"    The treatment of post-TIPS encephalopathy is similar to that of portosystemic encephalopathy in other settings. When PSE develops de novo or worsens after TIPS insertion, a search for potentially reversible precipitating factors is mandatory. Such factors include excessive protein intake, gastrointestinal bleeding, dehydration, azotemia, electrolyte and acid-base disturbances, infections, inappropriate use of medications, constipation, and worsening hepatic function. Precipitating factors should be treated, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    may be administered and the dose titrated to achieve two to four semiformed bowel movements daily. Protein restriction facilitates management of the encephalopathy but may worsen the nutritional state. This may be particularly important in those awaiting transplantation since there is a higher risk of perioperative complications and infections in severely malnourished patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PSE responds to medical treatment in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/12\">",
"     12",
"    </a>",
"    ]. In those who do not respond adequately to the measures described above, the following approaches can be tried:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addition of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or a nonabsorbable antibiotic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      may be useful, although there is little data to confirm the benefit of these agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link&amp;anchor=H10#H10\">",
"       \"Hepatic encephalopathy in adults: Treatment\", section on 'Oral antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The shunt can be occluded, although this reverses all of the potential benefits of the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/28\">",
"       28",
"      </a>",
"      ], or the shunt diameter can be reduced mechanically in specially designed stents [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Orthotopic liver transplant is the treatment of choice for refractory PSE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     UNIQUE TIPS-RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several complications that are directly related to the shunt, including hemolytic anemia and severe hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIPS-associated hemolytic anemia occurs in approximately 10 percent of patients and is diagnosed by the demonstration of new onset hemolysis with or without anemia in the absence of alternate causes (eg, spur cell anemia or Zieve's syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TIPS-associated hemolysis presents within 7 to 14 days after stent placement with an increase in serum bilirubin that is mostly unconjugated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. This is accompanied by a reticulocytosis and a decrease in serum haptoglobin. Whether overt anemia develops depends upon the balance between red cell production and destruction. Most patients have a minor (&lt;2",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    reduction in hemoglobin concentration, but severe anemia with high-output heart failure can occur. In such cases, blood transfusions are necessary to correct the anemia.",
"   </p>",
"   <p>",
"    It is believed that hemolysis results from injury to red cells from shear stress or direct mechanical trauma in the shunt with culling of abnormal cells in the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. The peripheral smear is not usually helpful but may show schistocytes (similar to those seen in other microangiopathies) in patients who develop severe anemia (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The usual natural history of TIPS-associated hemolysis is spontaneous resolution within 8 to 12 weeks in the majority of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/30\">",
"     30",
"    </a>",
"    ]. Why resolution occurs is not known. It may reflect covering of the metal wires with endothelium and smoothing the edges of the parenchymal tract, thereby reducing shear stress. Rare patients have been described in whom severe hemolysis persists past 12 weeks and who require orthotopic liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Severe hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series, severe hyperbilirubinemia (serum bilirubin &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [171",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    occurred in 5.4 percent of patients treated with TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/33\">",
"     33",
"    </a>",
"    ]. These patients did not appear to have hemolysis, and the only two risk factors that could be identified were nonalcoholic liver disease and a baseline prothrombin time before TIPS insertion of 17 seconds or more, indicative of decreased hepatic reserve. Compared with a control group of patients who did not develop this complication after TIPS insertion, those with severe hyperbilirubinemia had a markedly worse prognosis (95 versus 17 percent incidence of death or liver transplantation at 90 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vegetative infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have described the occurrence of vegetative infections involving the TIPS in eight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/34\">",
"     34",
"    </a>",
"    ]. These infections occurred weeks to months after TIPS insertion and presented with intermittent or continuous fever; in some patients, multiple temperature spikes occurred daily with an erratic pattern. The diagnosis was established by the presence of continuous bacteremia (ie, multiple positive blood cultures from different sites), the presence of vegetation in the TIPS or complete occlusion of the stent by a thrombus, and the absence of an alternate focus of infection despite an extensive search. The organisms were predominantly of enteric origin.",
"   </p>",
"   <p>",
"    TIPS infection can be successfully treated by intravenous antibiotics. Since the precise incidence of TIPS infection is unknown, no recommendations about antibiotic prophylaxis prior to such procedures can be made. However, it is common practice that prophylactic antibiotics are administered to patients prior to TIPS insertion using an agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g) or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam",
"    </span>",
"    (1.5 to 3 g), or in patients allergic to penicillin, a combination of an aminoglycoside with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, for patients who previously underwent TIPS insertion who now have a thrombus, it is our practice to provide antibiotic prophylaxis prior to interventions on the TIPS since the thrombosis is more likely to be seeded during bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     TIPS stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIPS insertion involves the disruption of hepatic parenchyma followed by creation of a high flow vascular tract. The hepatic response to the creation of this wound is the development of a pseudointima that grows in from the surrounding liver through the wire mesh of the stent to line the shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/7\">",
"     7",
"    </a>",
"    ]. This pseudointima is composed of an incomplete layer of lining endothelial cells with underlying collagenous matrix and mesenchymal cells interspersed between the collagen fibrils. With the introduction of covered stents, the problem of stent stenosis has been greatly decreased.",
"   </p>",
"   <p>",
"    The incidence of TIPS stenosis with uncovered stents is high and increases with time. In two series with a total of 222 patients with cirrhosis who underwent TIPS insertion, the rate of stent stenosis was approximately 75 percent at 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. By two years, virtually all surviving patients had developed TIPS stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two patterns of TIPS stenosis were noted: diffuse stenosis along the length of the stent (type 1 stenosis), and isolated focal narrowing at the hepatic venous end of the TIPS (type 2 stenosis). Both patterns respond well to dilation and placement of additional stents in series with the preexisting stents to shore up the dilated stents. The tendency for recurrence of portal hypertension due to pseudointimal hyperplasia persists for the first three to four years but tends to subside thereafter in surviving patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coated stents also reduce the incidence of TIPS stenosis and thus we suggest that all TIPS procedures be performed with such stents. In one study, 80 patients were randomized to receive a covered stent or an uncovered stent and were followed for two years. Shunt patency in the covered stent group was 76 percent versus 36 percent in the uncovered stent group (p&lt;0.05). Clinical relapse occurred in fewer patients in the covered stent group (10 versus 29 percent, p&lt;0.05). The covered stent group had a higher rate of being free of hepatic encephalopathy (67 versus 51 percent, p&lt;0.05). There was no significant difference in survival at two years (58 percent in the covered stent group versus 45 percent in the uncovered stent group) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Monitoring TIPS patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIPS stenosis an important cause of recurrent portal hypertension and variceal hemorrhage after TIPS placement with an uncovered stent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5,38\">",
"     5,38",
"    </a>",
"    ]. It is therefore mandatory to periodically monitor shunt patency. Angiography is the gold standard by which shunt patency is assessed and is also required for treatment of shunt stenosis. However, it is limited by its invasive nature and cost.",
"   </p>",
"   <p>",
"    Doppler sonography is often used as a noninvasive method to monitor shunt patency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/5,36,39-42\">",
"     5,36,39-42",
"    </a>",
"    ]. The primary limitation of sonography is its relative insensitivity in detecting stent stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/43\">",
"     43",
"    </a>",
"    ]. As an example, one study calculated the sensitivity and specificity of duplex ultrasonography compared with venography in 60 studies among 38 cirrhotic patients who had undergone TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/43\">",
"     43",
"    </a>",
"    ]. Ultrasonography had a sensitivity of 35 percent and a specificity of 83 percent for detecting TIPS stenosis or occlusion. It is possible that improvements in technology, such as echo-enhanced Doppler ultrasonography, will result in a sensitivity more closely approaching that of angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Helical CT angiography also has shown promise. In one study, 37 patients underwent 50 examinations, which were compared with findings on portography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15448/abstract/45\">",
"     45",
"    </a>",
"    ]. Helical CT angiograms correctly demonstrated 30 of 31 morphologic abnormalities (97 percent) and permitted the correct diagnosis of 22 of 24 hemodynamically significant abnormalities (92 percent). CT angiograms correctly demonstrated normal findings in 90 percent of cases.",
"   </p>",
"   <p>",
"    We perform Doppler sonograms between three and six months after TIPS and repeat sonography at six month intervals for the first two years. Angiography is reserved for those with sonographic evidence of stenosis or clinical features of recurrent portal hypertension (eg, worsening ascites). The low stenosis rates with covered stents have reduced the need for routine angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70135472\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three broad categories of complications associated with transjugular intrahepatic portosystemic shunt (TIPS) insertion:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Technical complications",
"     </li>",
"     <li>",
"      Complications related to creation of the portosystemic shunt",
"     </li>",
"     <li>",
"      Unique TIPS-related complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical complications may include the development of cardiac arrhythmias, inadvertent carotid artery or tracheal puncture, traversal of the liver capsule during attempts to enter the portal vein, creation of a tract between the shunt or the portal vein and the hepatic artery or bile ducts, and extrahepatic puncture of the portal vein. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technical complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary complication related to portosystemic shunting is the development of portosystemic encephalopathy. Portosystemic encephalopathy usually becomes clinically apparent two to three weeks after TIPS insertion. The occurrence of PSE six weeks or more after TIPS insertion is usually associated with gastrointestinal bleeding. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications related to portosystemic shunting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of post-TIPS encephalopathy is similar to that of portosystemic encephalopathy in other settings. When PSE develops de novo or worsens after TIPS insertion, a search for potentially reversible precipitating factors is mandatory. Such factors include excessive protein intake, gastrointestinal bleeding, dehydration, azotemia, electrolyte and acid-base disturbances, infections, inappropriate use of medications, constipation, and worsening hepatic function. Precipitating factors should be treated, if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"       \"Hepatic encephalopathy in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are several complications that are directly related to the shunt, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemolytic anemia (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Hemolytic anemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Severe hyperbilirubinemia (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Severe hyperbilirubinemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Vegetative infections (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Vegetative infections'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      TIPS stenosis (see",
"      <a class=\"local\" href=\"#H11\">",
"       'TIPS stenosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIPS stenosis an important cause of recurrent portal hypertension and variceal hemorrhage after TIPS placement with an uncovered stent. It is therefore mandatory to periodically monitor shunt patency. We perform Doppler sonograms between three and six months after TIPS and repeat sonography at six-month intervals for the first two years. Angiography is reserved for those with sonographic evidence of stenosis or clinical features of recurrent portal hypertension (eg, worsening ascites). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring TIPS patency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/1\">",
"      Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/2\">",
"      LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/3\">",
"      R&ouml;ssle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/4\">",
"      Pidlich J, Peck-Radosavljevic M, Kranz A, et al. Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias. J Clin Gastroenterol 1998; 26:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/5\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/6\">",
"      Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/7\">",
"      LaBerge JM, Ferrell LD, Ring EJ, Gordon RL. Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1993; 4:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/8\">",
"      Lind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology 1994; 106:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/9\">",
"      Theilmann L, Sauer P, Roeren T, et al. Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study. Hepatology 1994; 20:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/10\">",
"      Sauer P, Theilmann L, Herrmann S, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Hepatology 1996; 24:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/11\">",
"      Raat H, Stockx L, Ranschaert E, et al. Percutaneous hydrodynamic thrombectomy of acute thrombosis in transjugular intrahepatic portosystemic shunt (TIPS): a feasibility study in five patients. Cardiovasc Intervent Radiol 1997; 20:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/12\">",
"      Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/13\">",
"      Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996; 41:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/14\">",
"      Martinet JP, Fenyves D, Legault L, et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci 1997; 42:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/15\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/16\">",
"      Mutchnick MG, Lerner E, Conn HO. Portal-systemic encephalopathy and portacaval anastomosis: a prospective, controlled investigation. Gastroenterology 1974; 66:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/17\">",
"      Grace ND, Conn HO, Resnick RH, et al. Distal splenorenal vs. portal-systemic shunts after hemorrhage from varices: a randomized controlled trial. Hepatology 1988; 8:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/18\">",
"      Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/19\">",
"      R&ouml;ssle M, Piotraschke J. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy. Dig Dis 1996; 14 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/20\">",
"      Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008; 103:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/21\">",
"      Riggio O, Ridola L, Angeloni S, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol 2010; 53:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/22\">",
"      Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/23\">",
"      Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966; 51:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/24\">",
"      ZIEVE L, MENDELSON DF, GOEPFERT M. Shunt encephalomyelopathy. II. Occurrence of permanent myelopathy. Ann Intern Med 1960; 53:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/25\">",
"      Conn HO, R&ouml;ssle M, Levy L, Glocker FX. Portosystemic myelopathy: spastic paraparesis after portosystemic shunting. Scand J Gastroenterol 2006; 41:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/26\">",
"      Baliga P, Merion RM, Turcotte JG, et al. Preoperative risk factor assessment in liver transplantation. Surgery 1992; 112:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/27\">",
"      O'Keefe SJ, El-Zayadi AR, Carraher TE, et al. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980; 2:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/28\">",
"      Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/29\">",
"      Hauenstein KH, Haag K, Ochs A, et al. The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995; 194:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/30\">",
"      Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/31\">",
"      Sanyal AJ, Freedman AM, Purdum PP 3rd. TIPS-associated hemolysis and encephalopathy. Ann Intern Med 1992; 117:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/32\">",
"      Conn HO. Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome. Hepatology 1996; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/33\">",
"      Rouillard SS, Bass NM, Roberts JP, et al. Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: natural history and predictors of outcome. Ann Intern Med 1998; 128:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/34\">",
"      Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/35\">",
"      Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol 2010; 21:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/36\">",
"      Casado M, Bosch J, Garc&iacute;a-Pag&aacute;n JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/37\">",
"      Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/38\">",
"      LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/39\">",
"      Feldstein VA, Patel MD, LaBerge JM. Transjugular intrahepatic portosystemic shunts: accuracy of Doppler US in determination of patency and detection of stenoses. Radiology 1996; 201:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/40\">",
"      Ferral H, Foshager MC, Bjarnason H, et al. Early sonographic evaluation of the transjugular intrahepatic portosystemic shunt (TIPS). Cardiovasc Interv Radiol 1993; 15:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/41\">",
"      Kanterman RY, Darcy MD, Middleton WD, et al. Doppler sonography findings associated with transjugular intrahepatic portosystemic shunt malfunction. AJR Am J Roentgenol 1997; 168:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/42\">",
"      Dodd GD 3rd, Zajko AB, Orons PD, et al. Detection of transjugular intrahepatic portosystemic shunt dysfunction: value of duplex Doppler sonography. AJR Am J Roentgenol 1995; 164:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/43\">",
"      Owens CA, Bartolone C, Warner DL, et al. The inaccuracy of duplex ultrasonography in predicting patency of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 114:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/44\">",
"      Uggowitzer MM, Kugler C, Machan L, et al. Value of echo-enhanced Doppler sonography in evaluation of transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 1998; 170:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15448/abstract/45\">",
"      Chopra S, Dodd GD 3rd, Chintapalli KN, et al. Transjugular intrahepatic portosystemic shunt: accuracy of helical CT angiography in the detection of shunt abnormalities. Radiology 2000; 215:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1251 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15448=[""].join("\n");
var outline_f15_5_15448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H70135472\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complications related to access to the hepatic vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complications related to creation of the intrahepatic tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complications of portal vein manipulation and stent placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPLICATIONS RELATED TO PORTOSYSTEMIC SHUNTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      UNIQUE TIPS-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Severe hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vegetative infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TIPS stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Monitoring TIPS patency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70135472\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1251|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/10/3239\" title=\"figure 1\">",
"      Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/26/7598\" title=\"figure 2\">",
"      PSE after TIPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1251|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40302\" title=\"picture 1\">",
"      Occluded TIPS with fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 2\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3993?source=related_link\">",
"      Extrahepatic portal vein obstruction (portal vein thrombosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=related_link\">",
"      Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_5_15449="Bacterial pulmonary infections in HIV-infected patients";
var content_f15_5_15449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial pulmonary infections in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15449/contributors\">",
"     Gregory M Lucas, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15449/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15449/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/5/15449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pulmonary infections occur commonly in persons infected with the human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/1\">",
"     1",
"    </a>",
"    ]. The annual incidence of bacterial pneumonia in HIV-seropositive patients ranges from 5.5 to 29 per 100, compared with 0.7 to 10 per 100 in HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In developed countries, bacterial pathogens account for a majority of respiratory infections in HIV-infected individuals, particularly as Pneumocystis jirovecii incidence has declined profoundly in the era of highly effective antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bacterial pneumonias can occur throughout the course of HIV infection, they tend to develop more frequently in individuals with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immune status",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct relation between the CD4 count and the incidence of bacterial pneumonia was noted in a 2006 report: 4.9, 8.7, and 17.9 episodes occurred per 100 patient years with respective CD4 counts of &gt;500, 200 to 500, and &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infection is also a risk factor for recurrent pneumococcal pneumonia and bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H7#H7\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, the Centers for Disease Control and Prevention (CDC) added recurrent bacterial pneumonia as an AIDS&ndash;defining condition in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/9\">",
"     9",
"    </a>",
"    ]. Among HIV&ndash;infected patients, injection drug users (IDU), inner city inhabitants, smokers, and persons from developing countries are at highest risk for bacterial pneumonias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/2,3,10,11\">",
"     2,3,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of ART on incidence of pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of highly active antiretroviral therapy (HAART) in the United States has altered the incidence of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study from Johns Hopkins, 1898 HIV-infected patients with CD4 counts",
"    <span class=\"nowrap\">",
"     &lt;200/mm3",
"    </span>",
"    were examined from 1993 through the first six months of 1998 and had the following significant results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of bacterial pneumonia decreased progressively from 1993 to 1996 and 1997 (22.7 versus 12.3 and 9.1",
"      <span class=\"nowrap\">",
"       episodes/100",
"      </span>",
"      person-years, respectively).",
"     </li>",
"     <li>",
"      In a multivariate model, use of ART was associated with a 45 percent reduction in the risk for bacterial pneumonia.",
"     </li>",
"     <li>",
"      Depressed CD4 counts, a prior episode of Pneumocystis carinii pneumonia (PCP), and injection drug use remained significant risk factors for pneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent observational study of 3500 HIV-infected patients and 329,000 HIV-seronegative patients was conducted in Denmark from 1995 to 2007 to determine the incidence of hospitalization secondary to pneumonia during different time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/14\">",
"     14",
"    </a>",
"    ]. The incidence of hospitalizations in HIV-infected patients declined substantially from 51 per 1000 person-years during 1995 to 1996 to 20 per 1000 person-years during 2005 to 2007. Injection drug use, low current CD4 cell count, nadir CD4 cell count, increasing age, and absence of ART increased the risk of pneumonia. Although the risk of hospitalization for pneumonia in persons with HIV infection dramatically declined over the decade of study, a positive HIV serostatus remained a strong risk factor, even in persons with a CD4 cell count &ge;500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Data from the large randomized trial (n = 5472) of continuous versus intermittent antiretroviral therapy (Strategies for Management of Antiretroviral Therapy; SMART) were analyzed to determine if treatment discontinuation was associated with an increased risk of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/15\">",
"     15",
"    </a>",
"    ]. During a mean follow-up of 16 months, 116 participants (2.2 percent) developed at least one episode of bacterial pneumonia. The risk of pneumonia was significantly higher among patients treated with intermittent ART (hazard ratio, 1.55; 95% CI 1.07-2.25). Current smoking habits were also a significant contributor to risk; among patients assigned to continuous ART, smokers had a threefold increased risk of pneumonia compared to nonsmokers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"     \"Structured treatment interruptions in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with potent ART also decreases the burden of HIV RNA in bronchoalveolar lavage fluid with a concomitant decline in the absolute number of CD8+ T-lymphocytes in the alveolar space [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data as to whether the incidence of invasive pneumococcal disease per se has declined during the post-HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/12,17-19\">",
"     12,17-19",
"    </a>",
"    ]. In two studies, low CD4 counts &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and a history of PCP remained risk factors for invasive pneumococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/13,20\">",
"     13,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking, which is associated with a two- to fivefold increase in the risk of bacterial pneumonia and invasive pneumococcal disease in HIV-infected individuals, remains an important, modifiable risk factor in the ART era [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/4,17,21\">",
"     4,17,21",
"    </a>",
"    ]. In HIV-infected smokers, decreases in absolute CD4 cell counts and percentages and suppression of IL-1 beta and TNF-alpha production within the lung may contribute to risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other traditional risk factors that may be associated with pneumonia include pre-existing lung disease (eg, bronchiectasis), neutropenia, corticosteroids therapy, or severe malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECT OF PNEUMONIA ON THE HIV-INFECTED PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of bacterial pneumonia can have both short and long-term consequences in this patient population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute bacterial pneumonia can transiently depress the CD4 count. One study of 30 HIV-infected, antiretroviral-naive patients presenting with pneumococcal pneumonia found that the median CD4 count of 112",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      on the day of admission increased to 270",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      at one month follow-up without the use of antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The occurrence of bacterial pneumonia is associated with a permanent decline in pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/24\">",
"       24",
"      </a>",
"      ] and a two- to fivefold increase in long-term mortality compared to CD4-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/4,24,25\">",
"       4,24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial pathogens reported to cause community-acquired pneumonia in HIV&ndash;infected patients are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60437 \" href=\"UTD.htm?19/0/19467\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/3,10,11,26-35\">",
"     3,10,11,26-35",
"    </a>",
"    ]. Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus are the most commonly isolated bacteria, with S. pneumoniae accounting for the majority of cases in which a bacterial pathogen is isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/3,10,11,36-38\">",
"     3,10,11,36-38",
"    </a>",
"    ]. Legionella infection is uncommon, but occurs approximately 40 times more frequently in patients with AIDS than in the general population. Other uncommon infections include nocardia, pertussis, and Rhodococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/30-32,39\">",
"     30-32,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of invasive pneumococcal disease is greater in HIV-infected patients than the general population. In a CDC-sponsored study of pneumococcal disease using data from the Active Bacterial Core (ABC) surveillance and the National Health Interview Survey, the risk of invasive disease among risk groups was highest in adults with hematologic cancer or",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/40\">",
"     40",
"    </a>",
"    ]. Increased risk of invasive disease in HIV-infected patients may be partially explained by a predisposition for pneumococcal nasopharyngeal colonization. In a longitudinal cohort of 260 mother-infant pairs in Zambia, half of whom were HIV-seropositive, HIV infection was associated with an increased risk of colonization, particularly with pediatric serotypes covered by the 7-valent conjugate vaccine (RR 1.9; 95% CI 1.3-2.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA), usually harboring the Panton-Valentine leukocidin virulence factor, may cause rapidly progressive necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Although cases of pneumonia caused by CO-MRSA are relatively rare, they are characterized by high rates of morbidity and mortality. Risk factors for CO-MRSA colonization include HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pseudomonas aeruginosa, a nosocomial pathogen, is also implicated in community-acquired pneumonia. Factors associated with Pseudomonas pneumonia include prior hospitalization, antibiotic exposure, neutropenia, and advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/6,34,35,44-46\">",
"     6,34,35,44-46",
"    </a>",
"    ]. Pseudomonal infection in AIDS patients is associated with a 33 percent in-hospital mortality rate, poor one-year survival rates, and relapse of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/34,35,44\">",
"     34,35,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several pathophysiologic mechanisms underlie the susceptibility to infection with encapsulated, pyogenic organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deficiencies in humoral immunity, including HIV&ndash;related B lymphocyte dysfunction with impaired antibody responses to S. pneumoniae and P. aeruginosa, and depressed IgA and IgG2 subclass antibody levels. These functional changes are seen despite the presence of polyclonal hyperglobulinemia.",
"     </li>",
"     <li>",
"      Decreased serum and bronchoalveolar opsonic activity against pneumococcal capsular polysaccharides [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alveolar macrophage and neutrophil dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tracheitis and bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis and recurrent bronchitis, often associated with bronchiectasis, have also been reported in HIV-infected individuals. The isolated bacterial pathogens are similar to those causing pneumonia and include S. pneumoniae, H. influenzae, S. aureus, and P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial pneumonia in HIV&ndash;infected patients is most commonly caused by S. aureus and gram-negative organisms, including P. aeruginosa, K. pneumoniae, and Enterobacter species. These infections tend to occur late in the course of HIV infection and in patients with additional host factors predisposing to bacterial infections, such as neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/11,54\">",
"     11,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of bacterial pneumonia in the HIV&ndash;seropositive patient is similar to that in patients not infected with HIV. Most patients have an abrupt onset of fever, chills, cough with sputum production, dyspnea, and pleuritic chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The leukocyte count is generally elevated except in advanced immunosuppression. Bacteremia is frequently associated with pneumonia, with rates as high as 60 percent reported with S. pneumoniae infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchitis with bronchiectasis often presents in a similar fashion with fever and copious purulent sputum production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .) In comparison, bacterial tracheitis may present with signs and symptoms of upper airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common chest roentgenographic manifestation of bacterial pneumonia in the HIV&ndash;infected patient is segmental or lobar consolidation, although diffuse reticulonodular infiltrates and patchy lobar infiltrates may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. Certain patterns have been associated with specific infections, although such associations are of minimal diagnostic predictive value when assessing an individual patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhodococcus equi, an unusual gram-positive pathogen, has been reported as a cause of pneumonia in HIV&ndash;infected patients, generally in the setting of advanced immunosuppression. R. equi pneumonia is characterized by an indolent course with cavitary infiltrates, often in the upper lobes, mimicking tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/32,62\">",
"       32,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Upper lobe consolidation with cavitation has also been observed in pulmonary nocardiosis. Other radiographic findings described in association with Nocardia infection include diffuse interstitial infiltrates, reticulonodular infiltrates, pleural effusions, and solitary masses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography of the chest is helpful in defining the nature of the infiltrate, particularly in identifying subtle diffuse or \"ground-glass\" infiltrates that suggest P. jirovecii, a viral, or atypical bacterial pneumonia (eg, Chlamydia pneumoniae). In a South African study, in which 49 HIV-infected subjects with pulmonary symptoms were evaluated with both chest radiograph and high resolution computed tomography (HRCT), 40 subjects (82 percent) had lesions identified on HRCT that were not identified on chest radiograph, including \"ground-glass\" infiltrates, mediastinal lymphadenopathy, and pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiographs in patients with bronchitis and bronchiectasis are usually normal or may show only increased bronchovascular markings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The presence of bronchiectasis can be confirmed by CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common clinical dilemma is determining whether an HIV-infected patient presenting with pulmonary complaints has bacterial pneumonia, P. jirovecii, or tuberculosis. Although considerable overlap exists, simple clinical factors can be helpful. Admitting notes were reviewed in a retrospective study of 229 HIV-infected patients with verified hospital discharge diagnoses of P. jirovecii, bacterial pneumonia, or tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/64\">",
"     64",
"    </a>",
"    ]. Symptoms for less than seven days and a lobar infiltrate on chest radiograph had 94 percent specificity for bacterial pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial inpatient evaluation of an HIV-infected patient with suspected pneumonia should include a chest radiograph, sputum examination, white blood cell count, and blood cultures. Diagnostic evaluation can help determine if the presence of a particular pathogen may alter the initial choice of treatment (eg, Pseudomonas aeruginosa in a patient with advanced AIDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given the increased incidence of tuberculosis in HIV-infected patients, the diagnosis of TB should always be considered as well when evaluating the patient's history, risk factors, and chest x-ray findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Routine diagnostic workup is optional in a patient who is well enough to be treated as an outpatient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sputum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectorated sputum should be sent for Gram stain examination, acid-fast bacilli smear, and bacterial and mycobacterial culture. If the patient is at risk for P. jirovecii, an induced sputum should also be requested. Viral cultures should also be processed when the differential diagnosis is unclear or to assess whether a prior viral infection has led to bacterial superinfection. Rapid antigen tests for influenza are appropriate during the late fall and winter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. pneumonia can be isolated in blood cultures in up to 60 percent of HIV-infected patients with pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/55\">",
"     55",
"    </a>",
"    ]. In patients with pneumonia and high-grade bacteremia, gram-positive diplococci may occasionally be seen on Gram stain of the buffy coat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thoracocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnostic thoracentesis should be considered in any patient with a pleural effusion, particularly if there is a concern regarding empyema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment is dependent upon the clinical presentation. In patients presenting with typical symptoms of bacterial pneumonia plus focal consolidation on chest radiograph, initial antibiotic regimen will be directed at the most common community-acquired pathogens.",
"   </p>",
"   <p>",
"    The decision to treat as an outpatient or inpatient will depend on the clinical status and the reliability of the individual. The approach to treatment of community-acquired pneumonia is similar to that in the HIV-seronegative patient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, clinicians should also take into account current antibiotic prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for PCP prophylaxis) when making decisions about administering empiric treatment for intercurrent bacterial infections. In addition, the diagnosis of tuberculosis should be considered before initiating fluoroquinolone therapy, since patients with tuberculosis may initially respond clinically to fluoroquinolone therapy, which may lead to a delay in the diagnosis of tuberculosis and to the emergence of quinolone resistance in M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Outpatients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients who present with suspected bacterial infection with single lobar involvement and good respiratory status may be considered for outpatient therapy. Recommendations for treatment are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inpatients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients who have evidence of severe disease or severe immunocompromise should be admitted to the hospital for initial management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory isolation should be considered for possible influenza or tuberculosis until appropriate tests can be performed to rule out these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     General ward admissions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of community-acquired pneumonia in patients who require hospitalization begins with empiric therapy directed against the most common pathogens. If alternative diagnoses are also being considered, such as infection with P. jirovecii, empiric therapy should cover such pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     ICU admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients requiring admission to an ICU we recommend intravenous combination therapy with a potent anti-pneumococcal beta-lactam (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    2 g daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    1 g every eight hours) plus either a macrolide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    500 mg daily) or a respiratory fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    750 mg daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    400 mg daily).",
"   </p>",
"   <p>",
"    Empiric pseudomonas coverage should be included in patients with nosocomial pneumonia and in those HIV-infected patients with community-acquired pneumonia, who have advanced immunosuppression (eg, CD4 &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    prior Pseudomonas infection, bronchiectasis, or neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infection is associated with high rates of relapse from pseudomonas pneumonia. For this reason, we recommend treatment with two synergistic intravenous antibiotics (eg, an antipseudomonal B-lactam plus an aminoglycoside) for two weeks. In addition, maintenance therapy with an aerosolized aminoglycoside may be a consideration in patients with advanced HIV disease and documented relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For severely ill patients, we recommend early Gram's stain of respiratory secretions. If S. aureus is suspected clinically or by Gram's stain, we recommend the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, adjusted for renal function) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg every 12 hours) until the results of culture and susceptibility testing are known. Culture and sensitivities for S. pneumoniae are also helpful to determine the presence of penicillin resistance, which is more common in HIV infected patients, particularly in the setting of recurrent bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/8,66\">",
"     8,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proceeding to bronchoscopy may be necessary in those patients who fail to respond to empiric therapy or in patients who are at risk for P. jirovecii or tuberculosis. Combination therapy directed at bacterial as well as opportunistic infections may be necessary while awaiting the results of diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When culture results are available, specific pathogen-directed therapy should be provided. See the appropriate topics reviews for treatment recommendations for specific pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive strategies against bacterial pneumonia include immunizations, prophylactic antibiotics, and smoking cessation counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients have an impaired antibody response that declines with lower CD4 counts; vaccine failures have also been reported. For this reason, the Centers for Disease Control and Prevention (CDC) recommends that all HIV&ndash;infected patients be vaccinated as early as possible. This topic is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11047?source=see_link\">",
"     \"Pneumococcal immunization in HIV-infected patients\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     H. influenzae vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fortunately, the incidence of Haemophilus influenzae type B (HIB) disease in HIV-infected adults is low. Adults with advanced HIV disease do have a significantly increased rate of infection with H. influenzae, but most infections involve nontypeable strains for which the vaccine is not protective. HIB vaccine is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for adults infected with HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H12#H12\">",
"     \"Immunizations in HIV-infected patients\", section on 'Haemophilus influenzae vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for prophylactic antibiotics in HIV&ndash;infected patients with recurrent bacterial pneumonia has been suggested, although no formal recommendations exist.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     Trimethoprim",
"    </a>",
"    &ndash;sulfamethoxazole, when used as P. jirovecii prophylaxis, has been shown to decrease the risk for bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/3,4,67,68\">",
"     3,4,67,68",
"    </a>",
"    ]. In one report, for example, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    had a 67 percent reduction in the incidence of confirmed episodes of bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/3\">",
"     3",
"    </a>",
"    ]. For those patients receiving other forms of PCP prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    or aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ), antimicrobial prophylaxis with another antibiotic, is not recommended.",
"   </p>",
"   <p>",
"    The safety of discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for P. jirovecii prophylaxis when immune reconstitution has been achieved is well established, although such patients may be subsequently at risk for bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/69\">",
"     69",
"    </a>",
"    ]. However, one group reported similarly low rates of bacterial pneumonia in patients who discontinued prophylaxis compared to those who had not following immune reconstitution with HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrolide antibiotics are also effective in preventing bacterial infections in patients who are receiving these agents as prophylaxis for Mycobacterium avium complex disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Smoking cessation counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is highly prevalent in HIV-infected individuals, is a strong risk factor for bacterial pneumonia, and is linked to all-cause mortality among HIV-infected patients in the HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15449/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, multifaceted approaches to smoking cessation are warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31413623\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although bacterial pneumonias can occur throughout the course of HIV infection, they tend to develop more frequently in individuals with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors for pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The occurrence of bacterial pneumonia can lead to a decline in CD4 cell count and permanent changes on pulmonary function testing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effect of pneumonia on the HIV-infected patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus are the most commonly isolated pathogens associated with community-acquired pneumonia in this patient population. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of bacterial pneumonia in the HIV&ndash;seropositive patient is similar to that in patients not infected with HIV. Most patients have an abrupt onset of fever, chills, cough with sputum production, dyspnea, and pleuritic chest pain. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common chest roentgenographic manifestation of bacterial pneumonia in the HIV&ndash;infected patient is segmental or lobar consolidation, although diffuse reticulonodular infiltrates and patchy lobar infiltrates may also be seen. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial inpatient evaluation of an HIV-infected patient with suspected pneumonia should include a chest radiograph, sputum examination, white blood cell count, and blood cultures. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic evaluation and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with HIV-uninfected patients with pneumonia, the decision of whether to admit to the hospital or the ICU should be chiefly based on severity of illness, including hypoxia, hypotension, advanced age, and multi-lobar involvement. The patient&rsquo;s social support, ability to take oral medication, and degree of immunocompromise should also be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=see_link\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory isolation should be considered for possible influenza or tuberculosis until appropriate tests can be performed to rule out these conditions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Inpatients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients requiring admission to an ICU we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous combination therapy with a potent anti-pneumococcal beta-lactam (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      2 g daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      1 g every eight hours) plus either a macrolide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg daily) or a respiratory fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg daily).",
"     </li>",
"     <li>",
"      Empiric pseudomonas coverage for patients with nosocomial pneumonia and in those HIV-infected patients with community-acquired pneumonia, who have advanced immunosuppression (CD4 &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm3),",
"      </span>",
"      bronchiectasis, neutropenia or a history of pseudomonas infection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'ICU admission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, adjusted for renal function) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg every 12 hours) should be added to the antimicrobial therapeutic regimen for patients with documented or suspected methicillin-resistant Staphylococcus aureus pulmonary infection.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/1\">",
"      Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008; 134:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/2\">",
"      Caiaffa WT, Graham NM, Vlahov D. Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol 1993; 138:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/3\">",
"      Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/4\">",
"      Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/5\">",
"      Magnenat JL, Nicod LP, Auckenthaler R, Junod AF. Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients. Am Rev Respir Dis 1991; 144:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/6\">",
"      Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/7\">",
"      Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/8\">",
"      Turett GS, Blum S, Telzak EE. Recurrent pneumococcal bacteremia: risk factors and outcomes. Arch Intern Med 2001; 161:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/9\">",
"      1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/10\">",
"      Polsky B, Gold JW, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/11\">",
"      Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987; 82:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/12\">",
"      Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/13\">",
"      Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/14\">",
"      Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/15\">",
"      Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/16\">",
"      Twigg Iii HL, Weiden M, Valentine F, et al. Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 2008; 197:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/17\">",
"      Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/18\">",
"      Jordano Q, Falc&oacute; V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/19\">",
"      Barry PM, Zetola N, Keruly JC, et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/20\">",
"      Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/21\">",
"      Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/22\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/23\">",
"      Schleicher GK, Hopley MJ, Feldman C. CD4 T-lymphocyte subset counts in HIV-seropositive patients during the course of community-acquired pneumonia caused by Streptococcus pneumoniae. Clin Microbiol Infect 2004; 10:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/24\">",
"      Morris AM, Huang L, Bacchetti P, et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 2000; 162:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/25\">",
"      Osmond DH, Chin DP, Glassroth J, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary Complications of HIV Study Group. Clin Infect Dis 1999; 29:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/26\">",
"      Steinhart R, Reingold AL, Taylor F, et al. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 1992; 268:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/27\">",
"      Casadevall A, Dobroszycki J, Small C, Pirofski LA. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992; 92:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/28\">",
"      Schlamm HT, Yancovitz SR. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med 1989; 86:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/29\">",
"      Levine SJ, White DA, Fels AO. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1990; 141:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/30\">",
"      Javaly K, Horowitz HW, Wormser GP. Nocardiosis in patients with human immunodeficiency virus infection. Report of 2 cases and review of the literature. Medicine (Baltimore) 1992; 71:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/31\">",
"      Doebbeling BN, Feilmeier ML, Herwaldt LA. Pertussis in an adult man infected with the human immunodeficiency virus. J Infect Dis 1990; 161:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/32\">",
"      Cury JD, Harrington PT, Hosein IK. Successful medical therapy of Rhodococcus equi pneumonia in a patient with HIV infection. Chest 1992; 102:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/33\">",
"      Drabick JJ, Gasser RA Jr, Saunders NB, et al. Pasteurella multocida pneumonia in a man with AIDS and nontraumatic feline exposure. Chest 1993; 103:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/34\">",
"      Baron AD, Hollander H. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease. Am Rev Respir Dis 1993; 148:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/35\">",
"      Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/36\">",
"      Benito N, Ra&ntilde;&oacute; A, Moreno A, et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/37\">",
"      Rimland D, Navin TR, Lennox JL, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/38\">",
"      Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001; 184:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/39\">",
"      Men&eacute;ndez R, Cordero PJ, Santos M, et al. Pulmonary infection with Nocardia species: a report of 10 cases and review. Eur Respir J 1997; 10:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/40\">",
"      Kyaw MH, Rose CE Jr, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/41\">",
"      Gill CJ, Mwanakasale V, Fox MP, et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women. J Infect Dis 2008; 197:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/42\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/43\">",
"      Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/44\">",
"      Vidal F, Mensa J, Mart&iacute;nez JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999; 18:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/45\">",
"      Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/46\">",
"      Allen SH, Brennan-Benson P, Nelson M, et al. Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era. Postgrad Med J 2003; 79:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/47\">",
"      Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/48\">",
"      Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988; 158:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/49\">",
"      Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989; 3:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/50\">",
"      Moja P, Jalil A, Quesnel A, et al. Humoral immune response within the lung in HIV-1 infection. Clin Exp Immunol 1997; 110:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/51\">",
"      Wewers MD, Diaz PT, Wewers ME, et al. Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Am J Respir Crit Care Med 1998; 158:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/52\">",
"      Takahashi H, Oishi K, Yoshimine H, et al. Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis 2003; 37:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/53\">",
"      Eagan R, Twigg HL 3rd, French N, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. Clin Infect Dis 2007; 44:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/54\">",
"      Murray JF, Felton CP, Garay SM, et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med 1984; 310:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/55\">",
"      Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/56\">",
"      Chaisson RE. Bacterial pneumonia in patients with human immunodeficiency virus infection. Semin Respir Infect 1989; 4:133.",
"     </a>",
"    </li>",
"    <li>",
"     Gerberding JL, Drieger J, Sand MA. Recurrent bacteremic infection with S. pneumoniae in patients with AIDS virus (AV) infection. Program and abstracts of the Twenty&ndash;sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society of Microbiology 1986, p. 177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/58\">",
"      Pesola GR, Charles A. Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome. Chest 1992; 101:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/59\">",
"      Chechani V, Allam AA, Smith PR, et al. Bronchitis mimicking opportunistic lung infection in patients with human immunodeficiency virus infection/AIDS. N Y State J Med 1992; 92:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/60\">",
"      Verghese A, al-Samman M, Nabhan D, et al. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med 1994; 154:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/61\">",
"      Valor RR, Polnitsky CA, Tanis DJ, Sherter CB. Bacterial tracheitis with upper airway obstruction in a patient with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1992; 146:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/62\">",
"      Torres-Tortosa M, Arrizabalaga J, Villanueva JL, et al. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest 2003; 123:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/63\">",
"      Nyamande K, Lalloo UG, Vawda F. Comparison of plain chest radiography and high-resolution CT in human immunodeficiency virus infected patients with community-acquired pneumonia: a sub-Saharan Africa study. Br J Radiol 2007; 80:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/64\">",
"      Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998; 12:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/65\">",
"      Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/66\">",
"      Castillo EM, Rickman LS, Brodine SK, et al. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000; 28:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/67\">",
"      Mayer HB, Rose DN, Cohen S, et al. The effect of Pneumocystis carinii pneumonia prophylaxis regimens on the incidence of bacterial infections in HIV-infected patients. AIDS 1993; 7:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/68\">",
"      Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327:1842.",
"     </a>",
"    </li>",
"    <li>",
"     2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (US consensus guidelines) www.aidsinfo.nih.gov (Accessed on September 18, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/70\">",
"      Eigenmann C, Flepp M, Bernasconi E, et al. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. Clin Infect Dis 2003; 36:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/71\">",
"      Havlir DV, Dub&eacute; MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15449/abstract/72\">",
"      Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 2005; 19:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3716 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15449=[""].join("\n");
var outline_f15_5_15449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31413623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS FOR PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immune status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of ART on incidence of pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECT OF PNEUMONIA ON THE HIV-INFECTED PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tracheitis and bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSTIC EVALUATION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sputum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thoracocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Outpatients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inpatients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - General ward admissions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - ICU admission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      H. influenzae vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Smoking cessation counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31413623\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3716|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/0/19467\" title=\"table 1\">",
"      Bacterial pneumonia in HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11047?source=related_link\">",
"      Pneumococcal immunization in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_5_15450="Imaging studies in melanoma";
var content_f15_5_15450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Imaging studies in melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Kevin Donohoe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/5/15450/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/5/15450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of malignant melanoma of the skin, the most serious form of skin cancer, is increasing faster than that of any other cancer in the United States. Furthermore, this rising incidence is expected to continue for at least the next 20 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5112797#H5112797\">",
"     \"Risk factors for the development of melanoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to other skin cancers (ie, squamous or basal cell cancers), melanoma is an aggressive neoplasm that may spread in an unpredictable manner to involve virtually any organ of the body. Disease dissemination may occur by direct extension from the primary site, lymphatic spread to regional or distant lymph nodes, or by the hematogenous route. The most common sites of distant metastases are lungs and lymph nodes, followed by liver, gastrointestinal tract, brain, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/1\">",
"     1",
"    </a>",
"    ]. Almost all patients who die from melanoma do so with disseminated disease involving multiple organs; lung and intracranial metastases are the most frequent cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tumor (T), lymph node (N), metastasis (M) staging system is used for treatment planning and to assess prognosis for patients with melanoma. Key components include the histologic characteristics of the primary tumor, the extent of involvement of regional lymph nodes, and the presence or absence of metastatic disease, including the specific sites involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies using ultrasound, radiographic, and nuclear medicine techniques play an essential role in the staging and management of patients with melanoma. Imaging studies may be used to detect clinically occult disease, evaluate the extent of known disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    determine therapeutic response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging studies used for the diagnosis and management of melanoma, including comparison of imaging methods and limitations of imaging, as well as technical aspects that may influence the results of imaging are discussed here.",
"   </p>",
"   <p>",
"    The staging work-up of patients with suspected or histologically confirmed melanoma and the evaluation and management of regional nodes using lymphatic mapping and sentinel node biopsy procedure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link\">",
"     \"Staging work-up and surveillance after treatment of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern about the exposure to ionizing radiation with medical imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/6\">",
"     6",
"    </a>",
"    ]. Improvements in imaging technology and the development of new radiotracers have improved the ability to diagnosis many disease processes, including more accurate detection of metastatic disease. The use of these techniques to diagnose and manage neoplastic disease may not always improve patient outcomes and may increase the cost of health care and the exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/7\">",
"     7",
"    </a>",
"    ]. These issues need to be considered whenever a discussion of radiographic imaging is undertaken. However, when imaging is used judiciously in patients with melanoma, the theoretical risks due to radiation exposures are expected to be outweighed by the benefits gained from the accurate information.",
"   </p>",
"   <p>",
"    Melanoma most commonly metastasizes to regional nodes and skin. Disseminated metastases can be found in the lungs, brain, bowel, and a variety of other tissues. The differential diagnosis for unsuspected lesions found anywhere on radiographic studies in these patients almost always includes melanoma. Characteristic imaging appearances can help narrow the differential diagnosis of incidentally discovered lesions, but a definitive diagnosis requires histologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14425571\">",
"    <span class=\"h2\">",
"     Chest radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain chest radiographs are commonly used as initial imaging studies for patients with melanoma and for follow-up of patients with no evidence of metastatic disease. Chest radiographs are relatively inexpensive and use a relatively low radiation dose, about 0.1 mSv (millisievert), which is equivalent to the amount of background radiation a person would receive from the environment in less than two weeks.",
"   </p>",
"   <p>",
"    Despite the low radiation dose and cost, chest radiographs have a relatively poor sensitivity for metastatic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/8\">",
"     8",
"    </a>",
"    ]. This was illustrated by a retrospective series of 198 patients with clinical stage I or II melanoma who developed a recurrence after sentinel lymph node biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority of recurrences were detected by the patient. The initial recurrence was detected by chest radiograph, CT, or PET in 7, 13, and 1 percent of cases respectively. However, this study was heavily biased in that chest radiographs were performed every 6 to 12 months for all patients, while CT and PET were performed on a selective basis as clinically indicated.",
"   </p>",
"   <p>",
"    While chest x-rays can serve as a baseline for comparison with future studies, most patients with metastatic disease will be followed with more sensitive and specific imaging procedures, such as CT,",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    and MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14425591\">",
"    <span class=\"h2\">",
"     Computed tomography (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the aggressive nature of melanoma and the potential for early disease dissemination, extensive imaging (eg, CT of the chest, abdomen and pelvis, and brain, and abdominal ultrasound) of asymptomatic patients with stage I and II melanoma (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ) is usually not indicated since the detection rate is low, and the frequency of false positive findings is unacceptably high (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 50 percent of patients with locoregional disease (TNM stage III) or locally recurrent disease will ultimately exhibit systemic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Despite this, extensive staging evaluations that include CT scans of the brain, neck, chest, abdomen, and pelvis have a relatively low yield for detecting distant metastases in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H5#H5\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Clinical stage III and local recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiologic evaluation should be focused rather than exhaustive. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the morbidity associated with completion lymph node dissection and adjuvant interferon therapy in patients with a positive sentinel lymph node biopsy, a staging CT or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan of the torso may be recommended in order to identify the few patients whose disease is already too far advanced to benefit from this approach.",
"     </li>",
"     <li>",
"      The utility of routine brain imaging (ie, CT or magnetic resonance imaging [MRI]) in asymptomatic patients is controversial. Although many clinicians perform routine brain imaging only in symptomatic patients, at least one series suggests that up to 6 percent of asymptomatic individuals with stage III melanoma have clinically occult metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Brain'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reported results with CT can be difficult to interpret because of variations in equipment and technique. Older, slower CT scanners had poorer resolution than current generation multidetector scanners. More rapid scanning techniques available with current generation scanners are also less prone to bowel and respiratory motion artifacts during imaging. Further complicating the interpretation of reported results are the variety of imaging protocols available. CT scans can be done with or without contrast, and contrast can be administered intravenously, orally, or via both routes. &nbsp;",
"   </p>",
"   <p>",
"    Oral contrast administration is very helpful to distinguish bowel from nodes, vessels, female reproductive organs, and other structures in the abdomen and pelvis. However, high-density oral contrast agents can obscure the bowel wall, making bowel wall metastases more difficult to see. Low-density, water-based contrast agents or even plain water can be used, which allow excellent visualization of the bowel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous contrast agents improve the CT detection rate for metastatic disease substantially compared with non-contrast CT. Metastatic melanoma is typically hypervascular, with lesions appearing hyperdense compared to surrounding tissue on early phase contrast-enhanced CT. Disadvantages of intravenous contrast agents include potential allergic reactions and renal damage. The risk of allergic reactions can often be decreased by using non-ionic contrast agents and by avoiding contrast injection in patients with a history of allergies. While renal toxicity secondary to iodinated contrast is rare in patients with normally functioning kidneys, it is a significant risk in patients with preexisting diminished renal function or congestive heart failure. Iso-osmolar contrast agents have been shown to result in less renal toxicity in pooled data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple-phase imaging, which consists of several sets of CT images obtained at different times following contrast injection, is necessary to maximize the accuracy of CT for metastatic melanoma. Hypervascular lesions, such as melanoma metastases, have characteristic patterns of contrast wash-in and wash-out using this technique. For melanoma metastases, CT can be optimized with only two image sets, one prior to contrast injection, and the other during the portal venous phase (60 seconds following the start of contrast injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most radiology departments have established protocols for imaging neoplastic disease. Although the referring physician is not expected to know the details of specific protocols when ordering imaging studies, consultation with the radiologist may assist in optimizing use of imaging studies for patient management decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUCLEAR MEDICINE TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic detail provided by techniques such as CT and MRI in patients with melanoma are complemented by the physiologic information provided by nuclear medicine studies, particularly lymphoscintigraphy for sentinel lymph node (SLN) localization and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning for staging and following response to therapy. Other nuclear medicine studies, such as gallium scans and bone scans, were used in the past for detecting occult disease, but the widespread availability and superior accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    have replaced these studies almost entirely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose labeled with the positron emitter fluorine-18 (fluorodeoxyglucose, FDG) is transported into cells and phosphorylated by hexokinase no differently than unlabeled glucose. Unlike glucose-6-phosphate, FDG-6-phosphate is trapped inside the cell because it cannot continue through the glycolytic or gluconeogenic pathways. The greater metabolic demands of many neoplastic tissues, along with increased numbers of passive glucose cell membrane transport gateways (primarily GLUT-1), facilitate increased concentration of FDG in melanoma compared with normal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/20\">",
"     20",
"    </a>",
"    ]. Positron Emission Tomography (PET) cameras are designed to image the distribution of positron emitting isotopes, such as 18F. When combined with CT imaging",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    the metabolic information from the PET scan can be fused with the anatomic information from CT. As a result,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning is more accurate in the detection of melanoma metastases than CT, MRI, or PET alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Preliminary reports have also described the use of PET to monitor the response of melanoma to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=see_link&amp;anchor=H2#H2\">",
"     \"Thoracic positron emission tomography\", section on 'Technical issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with advanced melanoma,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be at least as sensitive and is definitely more specific than anatomic imaging modalities such as CT and MRI for the detection of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. Sensitivity is highest (90 percent or better) for metastases that are greater than 1 cm in diameter, but tumor deposits as small as 0.6 cm can be reliably seen in areas of low background activity, such as the lungs.",
"   </p>",
"   <p>",
"    The reported specificity for PET is from 43 to 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/27,32,33\">",
"     27,32,33",
"    </a>",
"    ]. False positive results may be due to inflammation (eg, recent surgery, infection, granulomatous disease), uptake in skeletal muscle, brown fat, or myocardium, normal activity in the bowel and urinary collecting system, or attenuation artifacts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/2\">",
"     2",
"    </a>",
"    ]. False negatives are seen with marrow stimulation and in nodes adjacent to brown fat uptake. Normal bowel concentration of tracer may also obscure bowel metastases. The specificity of PET (lack of false positives) has improved substantially with the addition of CT to PET",
"    <span class=\"nowrap\">",
"     (PET/CT).",
"    </span>",
"    Since the development of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanners, PET only scanners have virtually disappeared from the marketplace, although much of the early literature on PET is based on PET-only imaging machines.",
"   </p>",
"   <p>",
"    As with diagnostic CT scans, there are multiple ways to do a CT scan during",
"    <span class=\"nowrap\">",
"     PET/CT.",
"    </span>",
"    Some institutions prefer to do a full diagnostic CT scan as part of the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    study, complete with contrast administration. This approach allows the patient to avoid returning for an additional imaging procedure at a separate date, but it results in a higher radiation dose for all patients undergoing the procedure. At many institutions, the CT portion of the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is a low-dose scan for attenuation correction and general localization of disease. Although there is radiation exposure associated with the addition of a radiotracer such as FDG, the total radiation dose for a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    carried out in this way can be less than half that of a diagnostic CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The application of PET and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the staging evaluation of melanoma patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link\">",
"     \"Staging work-up and surveillance after treatment of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3689135\">",
"    <span class=\"h2\">",
"     SPECT/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    single photon emission computed",
"    <span class=\"nowrap\">",
"     tomography/computed",
"    </span>",
"    tomography",
"    <span class=\"nowrap\">",
"     (SPECT/CT)",
"    </span>",
"    provides anatomic information from CT that can be fused with physiologic information, such as lymphatic drainage patterns from Tc-99m sulfur colloid sentinel node imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    is particularly valuable for revealing the depth of nodal uptake and identifying adjacent structures prior to sentinel lymph node excision. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Lymph node imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Examples of situations in which",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    may be particularly valuable include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melanomas of the head and neck region &ndash; Along with the plethora of critical nerves, arteries and veins in the head and neck, lymphatic drainage is quite variable.",
"      <span class=\"nowrap\">",
"       SPECT/CT",
"      </span>",
"      is particularly helpful to reveal adjacent structures and depth of nodes. As an example, nodes deep to the sternomastoid and adjacent to vascular structures may require a different surgical approach than nodes superficial to the sternomastoid. Similarly, identification of nodes inside or outside the parotid gland can be important in surgical planning.",
"     </li>",
"     <li>",
"      Sentinel nodes in the groin &ndash; In contrast to planar imaging,",
"      <span class=\"nowrap\">",
"       SPECT/CT",
"      </span>",
"      can distinguish superficial inguinal nodes, which can be readily biopsied, from intrapelvic nodes. In some patients with a low probability of lymph node involvement, sampling of pelvic nodes may not be necessary. With planar only imaging, an incision and dissection down to the pelvic fascia may be needed before it could be determined that a node seen on planar images is deep to the fascia. &nbsp;",
"     </li>",
"     <li>",
"      In-transit nodes &ndash; Focal uptake of tracer outside the typical node beds, such as in the back, along the arm, or in the chest wall may be seen with in-transit nodes. In these cases, the depth of the site of uptake can again be important in surgical planning. Planar imaging alone may not be able to distinguish if a focus of tracer uptake is in the superficial soft tissues or inside the abdominal cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMAGING OF SPECIFIC SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are the most common site of melanoma metastases after skin, subcutaneous tissue, and lymph nodes. Tumor cells are trapped in the pulmonary parenchyma as blood flows through the pulmonary capillary bed.",
"   </p>",
"   <p>",
"    Contrast-enhanced CT scanning is the most widely used radiographic method for evaluating intrathoracic metastases because of its increased sensitivity for detecting small pulmonary nodules (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77904 \" href=\"UTD.htm?12/24/12687\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. CT is also superior to chest radiograph for demonstrating the mediastinal and hilar adenopathy that often accompanies parenchymal lesions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of lymphangitic spread, important issues for patients who have a potentially resectable isolated pulmonary metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link&amp;anchor=H8#H8\">",
"     \"Surgical management of metastatic melanoma\", section on 'Lung'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning is more sensitive than CT alone for detecting occult metastatic foci, including those in the lungs. Thus,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be helpful in patients with an apparently isolated pulmonary metastasis prior to planned thoracotomy and resection of the metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/46\">",
"     46",
"    </a>",
"    ]. If the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    study shows additional sites of disease, resection may not be indicated. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'PET/CT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is a common site of metastatic disease, with autopsy series suggesting the presence of hepatic involvement in up to 58 percent of patients with metastatic melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/11\">",
"     11",
"    </a>",
"    ]. Hepatic metastases are more common in patients with choroidal or mucosal primaries that more readily disseminate hematogenously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link\">",
"     \"Ocular melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When present, liver metastases are rarely solitary or isolated sites of disease. While the occasional patient with a solitary metastasis may benefit from surgical resection, radiofrequency ablation, or cryotherapy, systemic treatment is usually offered.",
"   </p>",
"   <p>",
"    Hepatic metastases may appear partially calcified or hemorrhagic, and if large, may contain areas of necrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52248 \" href=\"UTD.htm?35/38/36449\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/42\">",
"     42",
"    </a>",
"    ]. The enhancement pattern following contrast injection may be uniform, inhomogeneous, or ring-like. Because liver metastases from melanoma are hypervascular, they are best evaluated by multiphase CT in the non-contrast and portal contrast phases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT arterial portography (CTAP) utilizes the predominant hepatic arterial blood supply of metastases to enhance lesion detection by increased differential tumor enhancement relative to normal liver. The increased sensitivity of CTAP permits the detection of metastatic lesions less than 1 cm but requires catheter placement in the superior mesenteric artery and is therefore not practical in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link\">",
"     \"Computed tomography of the hepatobiliary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While multiphase CT is the initial procedure of choice for anatomic imaging of the liver, MRI may be useful in identifying solitary lesions such as hemangiomas or other benign entities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. MRI is also superior for demonstrating vascular involvement and identifying additional hepatic lesions in the patient thought to have a single isolated metastasis. On MRI, metastatic lesions appear as low signal areas on T1-weighted images and moderately high signal on T2-weighted images, while hemangiomas are characteristically well circumscribed, homogeneous lesions with low signal intensity (darker) on T1-weighted images and high intensity (brighter) on T2-weighted images. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On ultrasound, melanoma metastases are typically hypoechoic, and hemorrhage should be suspected if lesions appear heterogeneous. A subcapsular hepatic metastasis from melanoma can be a rare cause of a subcapsular hematoma or gross peritoneal hemorrhage.",
"   </p>",
"   <p>",
"    FDG-PET imaging is less sensitive for melanoma metastases in the liver than at other sites. The high level of glucose metabolism in the liver results in homogeneous FDG uptake that can obscure small metastatic foci.",
"   </p>",
"   <p>",
"    The preferred modality for detecting hepatic metastases is not clear and may need to be determined on a per-patient basis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. As",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and MRI techniques evolve, further investigation will be needed to determine the most accurate and cost-effective methods to detect liver metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the most frequent solid tumor that metastasizes to the small bowel. This was illustrated by one series, in which 110 of 2500 patients (4.4 percent) had gastrointestinal (GI) involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/55\">",
"     55",
"    </a>",
"    ]. Of these, 35 percent has lesions affecting the small bowel. The colon, stomach, and esophagus were involved in 14, 7, and 1 percent of cases, respectively. Metastatic lesions involving the GI tract are usually multiple, and involve the antimesenteric border of the bowel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical management of metastatic melanoma\", section on 'Gastrointestinal tract'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic melanoma involving the gastrointestinal (GI) tract may present with anemia, overt bleeding, pain, obstruction, or intussusception. Radiographic evaluation is indicated in patients with melanoma who present with any of these symptoms, or unexplained weight loss. In one series, fewer than 10 percent of patients with metastases to the bowel presented with pain, nausea, or vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/56\">",
"     56",
"    </a>",
"    ]. Complications of melanoma metastatic to bowel include perforation and obstruction due to intussusception.",
"   </p>",
"   <p>",
"    Radiographic studies that may be useful to evaluate the GI tract include abdominopelvic CT scan, small bowel follow-through, and enteroclysis. Small bowel enteroclysis is the most useful anatomic imaging procedure for evaluating small bowel lesions while an upper gastrointestinal series (UGI) is the best procedure for evaluation of symptoms referable to the esophagus and stomach.",
"   </p>",
"   <p>",
"    Melanoma may cause thickening of mucosal folds or multiple small submucosal lesions similar to metastatic deposits from lung or breast cancer, lymphoma, and Kaposi's sarcoma. Submucosal lesions may appear rounded or polypoid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/55\">",
"     55",
"    </a>",
"    ]. If the center of the tumor ulcerates (as the tumor outgrows its blood supply), the lesion can have a bull's eye or target appearance. This manifestation is considered pathognomonic for melanoma metastases to the bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If signs or symptoms of colonic lesions are present, the investigation should be guided by the patient presentation. If there is microscopic blood in the stool from a suspected colonic source, colonoscopy is very helpful for identifying the source. Biopsy or cautery, as needed, could also be performed with colonoscopy. If there is pain or signs of obstruction, then CT,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    or colonoscopy should be considered, depending on the patient presentation. Bowel obstruction caused by metastases encroaching on the bowel lumen is rare; obstruction is more commonly caused by intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are few published articles evaluating FDG-PET imaging of melanoma metastatic to the bowel, one report suggests that FDG-PET can detect bowel metastases that are missed by conventional anatomic imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lymph node imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary melanomas may metastasize through lymphatic channels to regional lymph nodes, the status of which is the most important prognostic factor for primary disease. Nodal metastases are frequently the initial manifestation of metastatic spread [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/43\">",
"     43",
"    </a>",
"    ]. Complete and accurate determination of nodal status is important not only for prognosis but also for decision-making regarding adjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination is an inaccurate predictor of nodal metastases; 20 percent of clinically node-negative patients have metastatic deposits, while 20 percent of those who are clinically node-positive have pathologically negative nodes. Furthermore, CT scanning is insensitive for the presence of small nodal metastases, and is also complicated by false positive results.",
"   </p>",
"   <p>",
"    This was illustrated by a series of 151 patients with primary melanoma who underwent CT of the chest and abdomen; those with primary lesions of the head or neck also underwent neck CT, and those with primary melanomas below the waist had a pelvic CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the 23 patients with histologically documented nodal involvement, none had a positive CT scan, although 15 had microscopic involvement only. Of the 29 cases with suspicious scans, the abnormalities were false positives in 24. Second primary malignancies (non-Hodgkin lymphoma, Hodgkin lymphoma, and renal cell carcinoma) were uncovered in three patients.",
"   </p>",
"   <p>",
"    Although",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    appears to be more accurate than other imaging studies for detecting metastatic disease, its value for the evaluation of regional nodes in patients with stage I or II melanoma is limited due to the intrinsic lack of specificity (CT) and sensitivity (PET) associated with the best available imaging for non-nodal metastases. In one series of 52 patients with Breslow depth &gt;1.5 mm and without palpable lymphadenopathy, PET (done within four weeks after wide excision) correctly identified nine regional lymph node metastases in four patients, none of whom had nodal metastases detected by conventional methods, including high-resolution ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/30\">",
"     30",
"    </a>",
"    ]. However, three additional PET \"lesions\" were incorrectly identified as metastases (false positives). Similar results were observed in another smaller study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in metastatic melanoma, FDG-PET cannot replace SLN biopsy. Microscopic disease associated with early lymphatic metastasis currently cannot be detected by any in-vivo imaging modality, including FDG-PET or nodal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362094274\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound may be used for multiple reasons in the staging and management of patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Ultrasound can be used in the staging of melanoma to evaluate node beds draining the primary site prior to sentinel node biopsy. This technique relies upon the detection of anatomic changes in nodes with metastatic disease. Nodes that demonstrate the loss of the normal fatty hilum can undergo fine needle aspiration. The ultrasonographic finding of peripheral hypervascularity in combination with other ultrasonographic findings increases the sensitivity of ultrasound for the diagnosis of nodal metastasis to approximately 82 percent with a positive predictive value of 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/65\">",
"     65",
"    </a>",
"    ]. Ultrasound might prevent sentinel node biopsy procedures in patients that are destined to have a complete lymph node dissection. Although ultrasound is not generally considered a substitute for SLN biopsy, serial ultrasounds may be useful for in some circumstances for monitoring to detect nodal recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound has not been widely utilized in staging melanoma, however, because it relies on anatomic changes that are not seen in nodal metastases until the tumor burden is substantial. Micrometastases will be missed by all currently available imaging modalities, including MRI, high-resolution CT,",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    and ultrasound. While the resolution of high-frequency ultrasound has shown promising results in superficial cervical chain nodes, as well as inguinal nodes in thin patients, axillary, iliac, and other deeper node beds are not as amenable to ultrasonographic examination. In addition, sentinel node scintigraphy can identify aberrant drainage pathways to unexpected node beds and in-transit nodes. &nbsp;",
"   </p>",
"   <p>",
"    In another report, high-resolution ultrasonography was helpful in differentiating cutaneous metastases of melanoma from blue nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/64\">",
"     64",
"    </a>",
"    ]. The low risk associated with cutaneous biopsy of suspicious lesions, particularly in patients with a history of melanoma, however, make the utility of this procedure questionable.",
"   </p>",
"   <p>",
"    The role of ultrasound in the diagnosis, staging and management of melanoma continues to evolve. The cost-effectiveness of the procedure by itself or in combination with sentinel node scintigraphy deserves further investigation. The procedure is not likely to replace sentinel node biopsy in all patients; however, as further studies become available, it may develop an important role in selected patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lymphoscintigraphy and subclinical adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sentinel lymph node (SLN) hypothesis maintains that tumor cells migrating from a primary tumor colonize the first (sentinel) node(s) receiving lymphatic drainage from the primary tumor site before involving other nodes.",
"   </p>",
"   <p>",
"    The pattern of lymphatic drainage to SLNs can be most accurately demonstrated by lymphoscintigraphy, a technique that has been available for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/67-72\">",
"     67-72",
"    </a>",
"    ]. Lymphoscintigraphy uses a radioactive colloid injected alone or in combination with local injection of blue dye (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/26/420?source=see_link\">",
"     isosulfan blue",
"    </a>",
"    ). When performed correctly, the SLN biopsy can provide important information that directly influences patient management and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/73-78\">",
"     73-78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intradermal injection of radioactive colloid around the primary tumor permits identification of sentinel node(s) in the majority of patients with the use of gamma camera imaging and a hand-held gamma probe at the time of surgery (",
"    <a class=\"graphic graphic_picture graphicRef51978 \" href=\"UTD.htm?7/5/7249\">",
"     picture 1",
"    </a>",
"    ). If the sentinel node is negative for metastasis, the remaining regional nodes are also very likely to be negative.",
"   </p>",
"   <p>",
"    The general procedure for SLN biopsy will be discussed here. The clinical application of the results from sentinel node studies in patients with melanoma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     SLN biopsy procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional lymphatic assessment is typically performed at the same time wide local excision is performed.",
"   </p>",
"   <p>",
"    While cutaneous lymphatic drainage pathways follow a generally predictable route to specific node beds, the specific node to first receive lymphatic flow within each node bed (the &ldquo;sentinel node&rdquo;) is difficult to determine using anatomic imaging techniques. In addition, the typical drainage pathways can vary substantially from person to person and region to region, with some areas of the skin draining to multiple node beds [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/79\">",
"     79",
"    </a>",
"    ]. The sentinel node lymphoscintigraphy procedure is therefore helpful in mapping patient-specific lymphatic flow patterns from the site of the primary lesion. &nbsp;",
"   </p>",
"   <p>",
"    The procedure begins with the intradermal injection of a radiolabeled tracer within 1.5 cm of the primary lesion. Proper injection technique usually is accompanied by the development of a tense wheal as the tracer is injected. Because the tracer is injected intradermally, many patients experience an uncomfortable burning at the site of injection for several seconds. Otherwise, the procedure is well-tolerated by most patients, particularly if the tracer is buffered to a neutral pH. The tracer is subsequently picked up by the local lymphatic channels and is then deposited in the nodal tissue receiving lymphatic flow from the site of injection. The SLN is often detected within 10 to 30 minutes of injection.",
"   </p>",
"   <p>",
"    Focal uptake of tracer can then be imaged using planar images from a standard nuclear medicine gamma camera, with single-photon emission computed tomography (SPECT) or with SPECT done concurrently with x-ray computed tomography",
"    <span class=\"nowrap\">",
"     (SPECT/CT)",
"    </span>",
"    for more precise localization of the site and depth of tracer uptake before the patient enters the surgical suite [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The following figures show typical images obtained with lymphoscintigraphy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76429 \" href=\"UTD.htm?19/34/20003\">",
"     image 3",
"    </a>",
"    ) and with",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82528 \" href=\"UTD.htm?12/53/13140\">",
"     image 4",
"    </a>",
"    ). When the primary lesion is located anywhere on the trunk, imaging should include both axillary and inguinal node beds, because of the variability of lymphatic drainage. The area between the injection site and sentinel node bed(s) should also be surveyed for in-transit nodes. In-transit nodes can also be seen with injection of a primary lesion on the extremities. &nbsp;Crossover to contralateral node beds is rare (eg, right leg draining to left inguinal or left iliac nodes), but should be considered when obtaining images.",
"   </p>",
"   <p>",
"    SLN scintigraphy has been validated in patients with local biopsy or focal excision of the primary lesion only. While there remains concern that prior wide local excision can change the normal patterns of lymphatic drainage around a primary melanoma, in at least one series wide local excision did not appear to adversely affect the results of a prior delayed lymphatic mapping and SLN biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care must be taken to image all nodal basins that may drain the site of the primary lesion, as SLNs in more than one nodal basin are common [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Unusual patterns of tracer concentration or unusual sites of nodal uptake should be directly communicated to the surgeon, as should the timing of appearance of nodes. If several nodes accumulate tracer in a nodal basin, it may be helpful to note which one(s) accumulated the tracer first. Flow images obtained with the gamma camera can assist in providing this information.",
"   </p>",
"   <p>",
"    Focal areas of tracer uptake may then be marked on the overlying skin by the nuclear medicine clinician for assistance with the initial guidance of the hand-held gamma probe during surgery. Although surgery can be delayed for up to 24 hours following tracer injection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/85\">",
"     85",
"    </a>",
"    ], radioactive decay of the tracer, and movement of the tracer through the SLN to secondary nodes are potential problems if surgery is delayed, particularly if smaller colloid particles or albumin are injected.",
"   </p>",
"   <p>",
"    In experienced hands, the procedural false negative rate (the inability to identify a sentinel lymph node that contains tumor) is typically 5 percent or less. Procedural false negatives should be distinguished from biologic false negatives, in which regional lymph node relapses are seen following biopsy of a true negative sentinel lymph node.",
"   </p>",
"   <p>",
"    Causes of false negative studies using lymphoscintigraphy for SLN localization include inadequate pathologic examination of the SLN, poor tracer injection technique, imaging the wrong nodal basin, not imaging all possible nodal basins, and complete replacement of the SLN with neoplastic disease causing the injected tracer to completely bypass the infiltrated node [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visualizing the sentinel node with the gamma camera or locating it with the intraoperative probe can be particularly difficult when the injection site is close to the draining node or node bed. This problem is often encountered with head and neck lesions. In these cases, injecting a smaller volume of injectate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a smaller amount of tracer activity close to the primary lesion (within 0.5 cm) can sometimes make resection of the injected material around the primary lesion easier, and subsequently allow easier localization of the sentinel node with the intraoperative probe.",
"    <span class=\"nowrap\">",
"     SPECT/CT",
"    </span>",
"    may also be particularly useful for separating injection site from adjacent nodes.",
"   </p>",
"   <p>",
"    The radiation dose associated with lymphoscintigraphy is trivial. Very small amounts of radioactivity are injected, and much of that activity is removed during surgery. When CT is added to SPECT",
"    <span class=\"nowrap\">",
"     (SPECT/CT),",
"    </span>",
"    the CT is typically not done with contrast, is only of a limited area, and is usually low-dose radiation, delivering only a fraction of the dose of diagnostic CT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin and subcutaneous tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of skin or subcutaneous tissue may be the first sign of metastatic disease. In one report, 17 of 45 patients (38 percent) with CT evidence of metastatic melanoma had subcutaneous nodules shown on CT; in five (11 percent), they were the only site of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/88\">",
"     88",
"    </a>",
"    ]. These lesions are particularly conspicuous on CT scans because of the density of the metastatic nodules relative to the low attenuation of the surrounding subcutaneous fat (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53362 \" href=\"UTD.htm?34/45/35551\">",
"     image 5",
"    </a>",
"    ). Imaging findings are rarely the first indicator of subcutaneous metastases, which can often be easily felt by the patient and physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many metastases to bone or muscle remain clinically undiagnosed during the patient's lifetime. However, when bone metastases are diagnosed, the prognosis is poor with average survival less than five months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bony metastatic disease is in the axial skeleton. This was illustrated in a study of 50 patients with a total of 127 metastatic lesions, 80 percent of which were in the axial skeleton, including 38 percent in the ribs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/90\">",
"     90",
"    </a>",
"    ]. All but one of these bone metastases was lytic, and most had an expansile appearance on plain radiograph. Periosteal reaction was uncommon.",
"   </p>",
"   <p>",
"    Radionuclide bone scanning is a simple and sensitive test for screening the entire skeleton for metastases, even though the majority of lesions are lytic on plain film. Activity of osteoblasts at the site of a bony metastasis can often be detected months before changes are seen on plain radiographs.",
"   </p>",
"   <p>",
"    Despite its sensitivity, bone scanning is not routinely ordered in patients with melanoma unless symptoms suggesting bone metastases are present. The low specificity of this technique, combined with the low incidence of metastases to bone early in the disease, results in an unacceptable number of false positive studies, which can be caused by benign processes such as trauma or degenerative joint disease. If bone pain develops in a patient with melanoma and plain radiographs are negative, the bone scan is a sensitive test to help rule out metastatic disease.",
"   </p>",
"   <p>",
"    CT is more specific than plain radiographs in the evaluation of bony lesions, and is particularly useful for the detection of purely lytic lesions, which may not be apparent by radionuclide bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/91\">",
"     91",
"    </a>",
"    ]. MRI is the best modality for evaluating marrow signal abnormalities and accompanying features such as hemorrhage or soft tissue masses; however, MRI also suffers from a low specificity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66636 \" href=\"UTD.htm?28/30/29167\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    More contemporary data suggest that",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be the most accurate test for the diagnosis of bone metastases. FDG uptake by metastatic deposits in the marrow can be detected before the surrounding osteocytes are stimulated to produce an osteoblastic and osteoclastic response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Muscle metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, melanoma metastases may invade muscle. On CT scanning, these metastases are hypervascular, and therefore they typically have high attenuation relative to muscle, following contrast injection. They may also present as low attenuation lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53160 \" href=\"UTD.htm?18/44/19137\">",
"     image 7",
"    </a>",
"    ).",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is more sensitive than CT for the diagnosis of muscle metastasis, but in one series the false-positive rate was high for isolated findings.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    was more accurate when multiple focal abnormalities were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Brain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of brain metastases is higher with melanoma than for most other malignancies. CNS metastases are the second most common cause of mortality after pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, melanoma is the third most common cause of brain metastases in the United States, after cancers of the lung and breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link\">",
"     \"Management of brain metastases in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On CT, intracranial metastases may enhance uniformly or in a ring-like pattern. Similar patterns are seen on gadolinium-enhanced MRI studies (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56550 \" href=\"UTD.htm?32/58/33698\">",
"     image 8",
"    </a>",
"    ). MRI is significantly more sensitive than CT for the detection of metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/13\">",
"     13",
"    </a>",
"    ], and also provides information about possible involvement of the spinal cord and leptomeninges.",
"   </p>",
"   <p>",
"    If there is hemorrhage associated with the metastasis, MRI can not only document the presence of blood, but it can also characterize the approximate age of the hemorrhage by detecting signal changes associated with the breakdown products of hemoglobin and RBC membrane integrity. Even in the absence of hemorrhage, melanoma may show a brighter signal on T1 sequences due to the paramagnetic effects of melanin. For these reasons, MRI is the study of choice to assess CNS disease.",
"   </p>",
"   <p>",
"    The indication for routine screening of the brain in asymptomatic patients with advanced local-regional disease is controversial. Some clinicians advocate studies to look for CNS involvement only in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/12,96\">",
"     12,96",
"    </a>",
"    ]. Others recommend brain imaging prior to definitive local therapy, citing data from one institution that found the rate of asymptomatic CNS metastases to be 6 percent in patients with known stage III disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is poor in detecting metastatic disease to the brain. Since the normal intense glucose uptake by the cortices of the cerebrum and cerebellum often obscures FDG uptake by metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas are more likely to metastasize to the heart than other solid tumors. Although most secondary pericardial tumors do not invade the myocardium, myocardial involvement is a classic feature of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/97\">",
"     97",
"    </a>",
"    ]. The clinical presentation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link&amp;anchor=H34#H34\">",
"     \"Cardiac tumors\", section on 'Secondary cardiac tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography is the primary imaging tool to establish the presence of a pericardial effusion. It is also useful to quantify the volume of an effusion and to evaluate its hemodynamic effects, particularly the presence of tamponade or constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT and MRI, although seldom used as a primary modality, also provide excellent information regarding pericardial effusion, especially when the fluid is loculated. Both techniques, which are usually performed for some other reason, are superior to echocardiography for determining whether an effusion is a transudate, exudate, or blood effusion.",
"   </p>",
"   <p>",
"    Large tumor masses in the pericardium can be recognized by all of these imaging studies. In some cases, however, a hematoma, usually of traumatic origin, can be mistaken for neoplasia. Echocardiography, particularly transesophageal echocardiography, complemented by ultrafast CT scanning and MRI imaging, can provide the degree of structural resolution necessary to ascertain the extent of local structural involvement. As with the brain, the use of PET for imaging metastases to the myocardium is not practical because of the normal myocardial concentration of glucose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other sites of metastatic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen, kidneys, adrenal glands, gallbladder, and breast are more likely to be involved with metastatic melanoma than with other more common tumors (eg, lung, breast, colon cancer).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typical CT appearance of splenic metastases consists of single or multiple ill-defined, low attenuation lesions, but they may also occasionally appear as well-defined cystic masses or target lesions.",
"     </li>",
"     <li>",
"      Melanoma metastases to the kidney may similarly be single or multiple, and solid or cystic. It is unusual for renal metastases to calcify, and this finding should raise suspicion for another etiology, such as a primary renal cell carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/98\">",
"       98",
"      </a>",
"      ]. Although melanoma uncommonly presents as a perirenal mass, it was the most frequent cause of such masses in one large series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/99\">",
"       99",
"      </a>",
"      ]. Ultrasound may be useful to further characterize a renal mass as cystic or solid (more likely to be malignant) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62586 \" href=\"UTD.htm?20/43/21170\">",
"       image 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=see_link\">",
"       \"Simple and complex renal cysts in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated adrenal metastases are also uncommon in melanoma, but they may be frequently seen in patients with widespread metastases. The adrenals were involved in 50 percent of cases in an autopsy series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/1\">",
"       1",
"      </a>",
"      ]. In older autopsy series, adrenal metastases were often large and frequently bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/44\">",
"       44",
"      </a>",
"      ]. Similar to their appearance at other metastatic sites, lesions may be solid or cystic. In a 2008 review from M. D. Anderson, a retrospective review of 1180 melanoma patients with distant metastasis showed 13 percent had adrenal metastases with a median survival of six months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Melanoma metastases to the gallbladder are rare (1 to 2 percent of cases at autopsy), but they represent the most common hematogenously spread metastasis to this organ [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/1\">",
"       1",
"      </a>",
"      ]. Gallbladder metastases are usually accompanied by liver metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/101\">",
"       101",
"      </a>",
"      ]. Metastatic disease in the gallbladder appears as mucosal deposits that become polypoid as they grow. These deposits are particularly suspicious for malignancy when larger than 7 mm.",
"     </li>",
"     <li>",
"      Melanoma is a more common tumor to metastasize to the breast than most other neoplastic diseases including lymphoma or leukemia. On mammography, melanoma metastases usually appear as multiple dense well-circumscribed masses without calcification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma can metastasize to a number of sites throughout the body. The route and pattern of metastatic disease are unpredictable. Radiographic and nuclear medicine imaging methods are critically important for the proper staging and follow-up of patients with this disease. The application of these imaging procedures in patients with melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link\">",
"     \"Staging work-up and surveillance after treatment of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphoscintigraphy and sentinel lymph node biopsy are integral components of primary management for patients who are clinically node-negative and at risk for regional lymph node involvement based upon the histologic characteristics of their primary tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\", section on 'Sentinel lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the evaluation and management of patients with advanced local-regional or metastatic disease is evolving [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/102\">",
"     102",
"    </a>",
"    ]. Overall,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is more accurate than CT or MRI alone in the diagnosis of metastasis, but there is no convincing evidence that the improved accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    over CT scanning alone improves patient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/5/15450/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. The role of all imaging procedures in patients with melanoma should be to identify and localize disease to help with prognostic assessment, stratification of for clinical trials and treatment selection. Given that",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be more accurate than other imaging methods, it is most useful for identifying other sites of metastatic disease before embarking on a metastasectomy for an apparently isolated lesion or for clarifying the nature of a suspicious lesion identified on CT scan.",
"   </p>",
"   <p>",
"    Chest and abdominal CT scans are the most common imaging tests for evaluating potential metastatic sites in the lungs, lymph nodes, and liver, and are indicated in any patient with new symptoms, physical findings, anemia, elevated lactic dehydrogenase, or chest x-ray abnormality.",
"   </p>",
"   <p>",
"    MRI of the brain is the procedure of choice for symptoms referable to the CNS, and is optional for asymptomatic patients with stage III or IV disease.",
"   </p>",
"   <p>",
"    For patients with skeletal complaints, plain radiographs, followed by bone scintigraphy, when necessary, are appropriate. If these studies are negative and the suspicion of metastatic disease remains high,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    or MRI may be indicated. MRI is a useful modality for evaluating the bone marrow and can detect disease before a bone scan becomes positive, but it is not as useful as whole-body",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for finding additional sites of involvement.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/1\">",
"      Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978; 135:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/2\">",
"      Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer 1978; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/3\">",
"      Jim&eacute;nez-Requena F, Delgado-Bolton RC, Fern&aacute;ndez-P&eacute;rez C, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010; 37:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/4\">",
"      Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20 Suppl 6:vi14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/5\">",
"      Ho Shon IA, Chung DK, Saw RP, Thompson JF. Imaging in cutaneous melanoma. Nucl Med Commun 2008; 29:847.",
"     </a>",
"    </li>",
"    <li>",
"     Ionizing radiation exposure of the population of the United States. In: National Council on Radiation Protection &amp; Measurements, 2009. Vol 160.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/7\">",
"      Brenner DJ. Medical imaging in the 21st century--getting the best bang for the rad. N Engl J Med 2010; 362:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/8\">",
"      Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/9\">",
"      Moore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2008; 15:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/10\">",
"      Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/11\">",
"      Shirkhoda A, Albin J. Malignant melanoma: correlating abdominal and pelvic CT with clinical staging. Radiology 1987; 165:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/12\">",
"      Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13:2104.",
"     </a>",
"    </li>",
"    <li>",
"     Magnetic Resonance Imaging of CNS, Mosby Yearbook, Inc., 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/14\">",
"      Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/15\">",
"      Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997; 4:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/16\">",
"      Paulsen SR, Huprich JE, Fletcher JG, et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics 2006; 26:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/17\">",
"      Cronin CG, Prakash P, Blake MA. Oral and IV contrast agents for the CT portion of PET/CT. AJR Am J Roentgenol 2010; 195:W5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/18\">",
"      Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/19\">",
"      Blake SP, Weisinger K, Atkins MB, Raptopoulos V. Liver metastases from melanoma: detection with multiphasic contrast-enhanced CT. Radiology 1999; 213:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/20\">",
"      Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 Suppl 2:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/21\">",
"      Mottaghy FM, Sunderk&ouml;tter C, Schubert R, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging 2007; 34:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/22\">",
"      Strobel K, Dummer R, Husarik DB, et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/23\">",
"      Pfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/24\">",
"      Steinert HC, von Schulthess GK. Initial clinical experience using a new integrated in-line PET/CT system. Br J Radiol 2002; 75 Spec No:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/25\">",
"      Hannah A, Feigen M, Quong G, et al. Use of [F]-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy. Otolaryngol Head Neck Surg 2000; 122:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/26\">",
"      Mijnhout GS, Comans EF, Raijmakers P, et al. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun 2002; 23:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/27\">",
"      Holder WD Jr, White RL Jr, Zuger JH, et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/28\">",
"      Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/29\">",
"      Paquet P, Hustinx R, Rigo P, Pi&eacute;rard GE. Malignant melanoma staging using whole-body positron emission tomography. Melanoma Res 1998; 8:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/30\">",
"      Rinne D, Baum RP, H&ouml;r G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/31\">",
"      Steinert HC, Huch B&ouml;ni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/32\">",
"      Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/33\">",
"      Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/34\">",
"      Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 2008; 19:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/35\">",
"      la Foug&egrave;re C, Pfluger T, Schneider V, et al. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT. Nuklearmedizin 2008; 47:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/36\">",
"      Gollub MJ, Hong R, Sarasohn DM, Akhurst T. Limitations of CT during PET/CT. J Nucl Med 2007; 48:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/37\">",
"      Brechtel K, Klein M, Vogel M, et al. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006; 47:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/38\">",
"      Pfannenberg AC, Aschoff P, Brechtel K, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007; 80:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/39\">",
"      Stoffels I, Boy C, P&ouml;ppel T, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA 2012; 308:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/40\">",
"      Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology 1991; 180:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/41\">",
"      Heaston DK, Putman CE, Rodan BA, et al. Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. AJR Am J Roentgenol 1983; 141:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/42\">",
"      Kostrubiak I, Whitley NO, Aisner J, et al. The use of computed body tomography in malignant melanoma. JAMA 1988; 259:2896.",
"     </a>",
"    </li>",
"    <li>",
"     Balch CM, Soong SJ, Shaw H, et al. An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous Melanoma, Balch C, Milton G (Eds), JB Lippincott, Philadelphia 1985. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/44\">",
"      Fishman EK, Kuhlman JE, Schuchter LM, et al. CT of malignant melanoma in the chest, abdomen, and musculoskeletal system. Radiographics 1990; 10:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/45\">",
"      Abdi EA, Terry T. Lymphography and computed tomography in lymph node metastases from malignant melanoma. Acta Radiol 1988; 29:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/46\">",
"      Dalrymple-Hay MJ, Rome PD, Kennedy C, et al. Pulmonary metastatic melanoma -- the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg 2002; 21:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/47\">",
"      Heiken JP, Weyman PJ, Lee JK, et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/48\">",
"      Nelson RC, Chezmar JL, Sugarbaker PH, Bernardino ME. Hepatic tumors: comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989; 172:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/49\">",
"      Ferrucci JT. Liver tumor imaging: current concepts. AJR Am J Roentgenol 1990; 155:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/50\">",
"      Paley MR, Ros PR. Hepatic metastases: computed tomography versus magnetic resonance imaging in 1997. Endoscopy 1997; 29:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/51\">",
"      Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am 1998; 36:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/52\">",
"      Ghanem N, Altehoefer C, H&ouml;gerle S, et al. Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography. Eur J Radiol 2005; 54:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/53\">",
"      Yang M, Martin DR, Karabulut N, Frick MP. Comparison of MR and PET imaging for the evaluation of liver metastases. J Magn Reson Imaging 2003; 17:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/54\">",
"      Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 2006; 32:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/55\">",
"      Reintgen DS, Thompson W, Garbutt J, Seigler HF. Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery 1984; 95:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/56\">",
"      Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg 1991; 162:428.",
"     </a>",
"    </li>",
"    <li>",
"     Herlinger H, Maglinte D. Clinical Radiology of the Small Intestine, WB Saunders,, Philadelphia 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/58\">",
"      Tatlidil R, Mandelkern M. FDG-PET in the detection of gastrointestinal metastases in melanoma. Melanoma Res 2001; 11:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/59\">",
"      Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/60\">",
"      Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998; 16:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/61\">",
"      Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/62\">",
"      Mijnhout GS, Hoekstra OS, van Lingen A, et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003; 56:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/63\">",
"      Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/64\">",
"      Samimi M, Perrinaud A, Naouri M, et al. High-resolution ultrasonography assists the differential diagnosis of blue naevi and cutaneous metastases of melanoma. Br J Dermatol 2010; 163:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/65\">",
"      Voit C, Van Akkooi AC, Sch&auml;fer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol 2010; 28:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/66\">",
"      Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol 2009; 27:5614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/67\">",
"      Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/68\">",
"      Dufresne EN, Kaplan WD, Zimmerman RE, Rose CM. The application of internal mammary lymphoscintigraphy to planning of radiation therapy. J Nucl Med 1980; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/69\">",
"      Jones D, Hanelin L, Christopherson D, et al. Radiotherapy treatment planning using lymphoscintigraphy. Int J Radiat Oncol Biol Phys 1986; 12:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/70\">",
"      Siddon RL, Chin LM, Zimmerman RE, et al. Utilization of parasternal lymphoscintigraphy in radiation therapy of breast carcinoma. Int J Radiat Oncol Biol Phys 1982; 8:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/71\">",
"      Campisi C, Boccardo F. Role of microsurgery in the management of lymphoedema. Int Angiol 1999; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/72\">",
"      Sacks GA, Sandler MP, Born ML, et al. Lymphoscintigraphy as an adjunctive procedure in the perioperative assessment of patients undergoing microlymphaticovenous anastomoses. Clin Nucl Med 1983; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/73\">",
"      Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/74\">",
"      Belli F, Lenisa L, Clemente C, et al. Sentinel node biopsy and selective dissection for melanoma nodal metastases. Tumori 1998; 84:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/75\">",
"      Yudd AP, Kempf JS, Goydos JS, et al. Use of sentinel node lymphoscintigraphy in malignant melanoma. Radiographics 1999; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/76\">",
"      Edwards MJ, Martin KD, McMasters KM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Surg Oncol 1998; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/77\">",
"      McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999; 6:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/78\">",
"      Ross MI. Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Semin Surg Oncol 1996; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/79\">",
"      Reynolds HM, Walker CG, Dunbar PR, et al. Functional anatomy of the lymphatics draining the skin: a detailed statistical analysis. J Anat 2010; 216:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/80\">",
"      Vermeeren L, van der Ploeg IM, Olmos RA, et al. SPECT/CT for preoperative sentinel node localization. J Surg Oncol 2010; 101:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/81\">",
"      van der Ploeg IM, Kroon BB, Vald&eacute;s Olmos RA, Nieweg OE. Evaluation of lymphatic drainage patterns to the groin and implications for the extent of groin dissection in melanoma patients. Ann Surg Oncol 2009; 16:2994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/82\">",
"      Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 2006; 107:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/83\">",
"      Uren RF, Howman-Giles RB, Shaw HM, et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 34:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/84\">",
"      Uren RF, Howman-Giles R, Thompson JF. Lymphatic drainage from the skin of the back to retroperitoneal and paravertebral lymph nodes in melanoma patients. Ann Surg Oncol 1998; 5:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/85\">",
"      White DC, Schuler FR, Pruitt SK, et al. Timing of sentinel lymph node mapping after lymphoscintigraphy. Surgery 1999; 126:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/86\">",
"      Ege GN. Internal mammary lymphoscintigraphy. The rationale, technique, interpretation and clinical application: a review based on 848 cases. Radiology 1976; 118:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/87\">",
"      Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/88\">",
"      Patten RM, Shuman WP, Teefey S. Subcutaneous metastases from malignant melanoma: prevalence and findings on CT. AJR Am J Roentgenol 1989; 152:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/89\">",
"      Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/90\">",
"      Fon GT, Wong WS, Gold RH, Kaiser LR. Skeletal metastases of melanoma: radiographic, scintigraphic, and clinical review. AJR Am J Roentgenol 1981; 137:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/91\">",
"      Patten RM, Shuman WP, Teefey S. Metastases from malignant melanoma to the axial skeleton: a CT study of frequency and appearance. AJR Am J Roentgenol 1990; 155:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/92\">",
"      Kurli M, Reddy S, Tena LB, et al. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 2005; 140:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/93\">",
"      Aydin A, Yu JQ, Zhuang H, Alavi A. Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma. Clin Nucl Med 2005; 30:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/94\">",
"      Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/95\">",
"      Mansour AA 3rd, Kelley MC, Hatmaker AR, et al. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. Ann Surg Oncol 2010; 17:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/96\">",
"      Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/97\">",
"      Savoia P, Fierro MT, Zaccagna A, Bernengo MG. Metastatic melanoma of the heart. J Surg Oncol 2000; 75:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/98\">",
"      Kamel IR, Kruskal JB, Gramm HF. Imaging of abdominal manifestations of melanoma. Crit Rev Diagn Imaging 1998; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/99\">",
"      Merine D, Fishman EK, Jones B, Siegelman SS. Enteroenteric intussusception: CT findings in nine patients. AJR Am J Roentgenol 1987; 148:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/100\">",
"      Mittendorf EA, Lim SJ, Schacherer CW, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 2008; 195:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/101\">",
"      Shimkin PM, Soloway MS, Jaffe E. Metastatic melanoma of the gallbladder. Am J Roentgenol Radium Ther Nucl Med 1972; 116:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/102\">",
"      Belhocine TZ, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/103\">",
"      Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/5/15450/abstract/104\">",
"      Iagaru A, Quon A, Johnson D, et al. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 2007; 9:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7625 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15450=[""].join("\n");
var outline_f15_5_15450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIOGRAPHIC IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14425571\">",
"      Chest radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14425591\">",
"      Computed tomography (CT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUCLEAR MEDICINE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PET/CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3689135\">",
"      SPECT/CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMAGING OF SPECIFIC SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lymph node imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362094274\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lymphoscintigraphy and subclinical adenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - SLN biopsy procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin and subcutaneous tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bone metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Muscle metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other sites of metastatic involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7625|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/24/12687\" title=\"diagnostic image 1\">",
"      Melanoma pleural metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/38/36449\" title=\"diagnostic image 2\">",
"      Necrotic hepatic met melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/34/20003\" title=\"diagnostic image 3\">",
"      Intraop SLN mapping radioactive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/53/13140\" title=\"diagnostic image 4\">",
"      Fused SPECT-CT of right inguinal sentinel node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/45/35551\" title=\"diagnostic image 5\">",
"      Subcutaneous met melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/30/29167\" title=\"diagnostic image 6\">",
"      MRI vertebral mets melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/44/19137\" title=\"diagnostic image 7\">",
"      Muscular metastases melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/58/33698\" title=\"diagnostic image 8\">",
"      Brain MRI CNS met melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/43/21170\" title=\"diagnostic image 9\">",
"      Melanoma renal metastasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7625|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/5/7249\" title=\"picture 1\">",
"      Gamma probe for SLN detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=related_link\">",
"      Computed tomography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=related_link\">",
"      Ocular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=related_link\">",
"      Thoracic positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_5_15451="Epidemiology homelessness";
var content_f15_5_15451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiology of homelessness in the United States: January 2005",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        One day total (point prevalence)*",
"       </td>",
"       <td>",
"        744,313",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Homeless during 2005",
"       </td>",
"       <td>",
"        2.3 - 3.5 million",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic (long-term or repeat)",
"       </td>",
"       <td>",
"        23 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In shelters or transitional housing",
"       </td>",
"       <td>",
"        56 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unsheltered",
"       </td>",
"       <td>",
"        44 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Individuals",
"       </td>",
"       <td>",
"        59 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Families with Children",
"       </td>",
"       <td>",
"        41 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of families",
"       </td>",
"       <td>",
"        98,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excludes persons in institutions or \"doubled-up\" (see text).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Homelessness Counts by National Alliance to End Homelessness, January 2007. Available at www.endhomelessness.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15451=[""].join("\n");
var outline_f15_5_15451=null;
var title_f15_5_15452="Low risk ciTBI child";
var content_f15_5_15452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Findings associated with very low risk of significant traumatic brain injury in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age, years",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical criteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       &lt;2",
"      </td>",
"      <td>",
"       Normal mental status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normal behavior per routine caregiver",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No LOC&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No severe mechanism of injury&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No nonfrontal scalp hematoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No evidence of skull fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       &ge;2 to 18",
"      </td>",
"      <td>",
"       Normal mental status&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No LOC",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No severe mechanism of injury&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No vomiting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No severe headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No signs of basilar skull fracture&yen;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TBI: traumatic brain injury; GCS: Glasgow coma scale; LOC: loss of consciousness.",
"     <br>",
"      * Significant TBI: death or injury that requires neurosurgical intervention, endotracheal intubation for longer than 24 hours, or hospitalization for 2 or more nights.",
"      <br>",
"       &bull;Including very brief (&lt;5 seconds) loss of consciousness associated with low risk mechanisms for head trauma.",
"       <br>",
"        &Delta; Severe mechanism of injury: fall &gt;0.9 m (3 feet); head struck by high impact object; motor vehicle collision with patient ejection, death of another passenger, or rollover; pedestrian or bicyclist without helmet struck by a motorised vehicle.",
"        <br>",
"         &loz; Signs of altered mental status: agitation, somnolence, repetitive questioning, or slow response to verbal questioning.",
"         <br>",
"          &sect; As for children under 2 years of age except fall &gt;1.5 m (5 feet) considered severe.",
"          <br>",
"           &yen;Early signs of basilar skull fracture at presentation include hemotympanum, CSF rhinorrhea, and CSF otorrhea; late signs of basilar skull fracture, occurring up to 24 hours after injury, include raccoon eyes and post auricular hematoma (Battle sign).",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kuppermann, N, Holmes JF, Dayan, PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. Lancet 2009; 374:1160.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15452=[""].join("\n");
var outline_f15_5_15452=null;
var title_f15_5_15453="Development history";
var content_f15_5_15453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63435%7EPEDS%2F68449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63435%7EPEDS%2F68449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical history in developmental surveillance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prenatal risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of prenatal illness/infectious disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal drug/alcohol/tobacco use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous miscarriage or stillbirth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perinatal risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prematurity, particularly gestational age &le;30 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very low birth weight (&lt;1500 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe hyperbilirubinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failed newborn hearing screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pertinent past medical history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of recurrent or chronic otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vision and hearing concerns and assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous hospitalizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic illness (eg, asthma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Developmental and behavioral history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timeliness of acquisition of previous milestones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep patterns and duration (eg, trouble falling asleep or staying asleep; symptoms of obstructive sleep apnea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Play interests",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the medical evaluation when assessing development",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Looking for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head circumference",
"       </td>",
"       <td>",
"        Microcephaly, macrocephaly, altered growth velocity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight and height",
"       </td>",
"       <td>",
"        <p>",
"         Growth deficiency (failure to thrive, short stature)",
"        </p>",
"        <p>",
"         Overgrowth",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General appearance",
"       </td>",
"       <td>",
"        Dysmorphic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        Visual acuity, tracking, strabismus, cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ears",
"       </td>",
"       <td>",
"        Unusual shape or placement, signs of recurrent otitis media or chronic otitis media with effusion, hearing acuity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdomen",
"       </td>",
"       <td>",
"        Hepatosplenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Neurocutaneous lesions and vascular markings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic examination",
"       </td>",
"       <td>",
"        Persistent primitive reflexes; abnormalities of symmetry, tone, strength, deep tendon reflexes, protective reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation*",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Looking for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin/hematocrit",
"       </td>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood lead level",
"       </td>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional evaluation may be warranted for some children with historical or examination findings suggestive of a medical etiology. The evaluation should be tailored to the clinical findings and may include thyroid function testing, genetic testing, metabolic screening, and/or neuroimaging or encephalography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15453=[""].join("\n");
var outline_f15_5_15453=null;
var title_f15_5_15454="Dosing for vancomycin";
var content_f15_5_15454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric dosing of vancomycin (for adults)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Initial dose: 20 mg/kg (rounded to nearest 250 mg)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Maintenance dose: based on estimated creatinine clearance, weight and target trough (see below)*",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Creatinine clearance (ml/min)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Weight (actual)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        50-59 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        60-69 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        70-79 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        80-89 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        90-99 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        100 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Target trough 15-20 mcg/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;10",
"       </td>",
"       <td colspan=\"6\">",
"        Repeat dose when spot serum concentration &le;20 mcg/ml)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        10-19",
"       </td>",
"       <td>",
"        750 mg q 48 h",
"       </td>",
"       <td>",
"        1000 mg q 48 h",
"       </td>",
"       <td>",
"        1000 mg q 48 h",
"       </td>",
"       <td>",
"        1250 mg q 48 h",
"       </td>",
"       <td>",
"        1250 mg q 48 h",
"       </td>",
"       <td>",
"        1500 mg q 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        20-29",
"       </td>",
"       <td>",
"        500 mg q 24 h",
"       </td>",
"       <td>",
"        750 mg q 24 h",
"       </td>",
"       <td>",
"        1000 mg q 36 h",
"       </td>",
"       <td>",
"        1250 mg q 36 h",
"       </td>",
"       <td>",
"        1250 mg q 36 h",
"       </td>",
"       <td>",
"        1250 mg q 36 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        30-39",
"       </td>",
"       <td>",
"        750 mg q 24 h",
"       </td>",
"       <td>",
"        750 mg q 24 h",
"       </td>",
"       <td>",
"        1000 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        40-49",
"       </td>",
"       <td>",
"        750 mg q 18 h",
"       </td>",
"       <td>",
"        750 mg q 18 h",
"       </td>",
"       <td>",
"        1000  mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        50-59",
"       </td>",
"       <td>",
"        750 mg q 18 h",
"       </td>",
"       <td>",
"        1000 mg q 18 h",
"       </td>",
"       <td>",
"        1000 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1500 mg q 18 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        60-69",
"       </td>",
"       <td>",
"        750 mg q 12 h",
"       </td>",
"       <td>",
"        750 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        70-79",
"       </td>",
"       <td>",
"        750 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        80-89",
"       </td>",
"       <td>",
"        750 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        90-99",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt; = 100",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1750 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Target trough 10-15 mcg/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;10 ml/min",
"       </td>",
"       <td colspan=\"6\">",
"        Repeat dose when spot serum concentration &le;15 mcg/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        10-19",
"       </td>",
"       <td>",
"        1000 mg q 72 h",
"       </td>",
"       <td>",
"        1250 mg q 72 h",
"       </td>",
"       <td>",
"        1250 mg q 72 h",
"       </td>",
"       <td>",
"        1500 mg q 72 h",
"       </td>",
"       <td>",
"        1500 mg q 72 h",
"       </td>",
"       <td>",
"        1750 mg q 72 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        20-29",
"       </td>",
"       <td>",
"        1000 mg q 48 h",
"       </td>",
"       <td>",
"        1000 mg q 48 h",
"       </td>",
"       <td>",
"        1250 mg q 48 h",
"       </td>",
"       <td>",
"        1500 mg q 48 h",
"       </td>",
"       <td>",
"        1500 mg q 48 h",
"       </td>",
"       <td>",
"        1750 mg q 48 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        30-39",
"       </td>",
"       <td>",
"        1000 mg q 36 h",
"       </td>",
"       <td>",
"        1000 mg q 36 h",
"       </td>",
"       <td>",
"        1250 mg q 36 h",
"       </td>",
"       <td>",
"        1500 mg q 36 h",
"       </td>",
"       <td>",
"        1500 mg q 36 h",
"       </td>",
"       <td>",
"        1750 mg q 36 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        40-49",
"       </td>",
"       <td>",
"        1000 mg q 24 h",
"       </td>",
"       <td>",
"        1000 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1500 mg q 24 h",
"       </td>",
"       <td>",
"        1500 mg q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        50-59",
"       </td>",
"       <td>",
"        1000 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1250 mg q 24 h",
"       </td>",
"       <td>",
"        1500 mg q 24 h",
"       </td>",
"       <td>",
"        1500 mg q 24 h",
"       </td>",
"       <td>",
"        1750 mg q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        60-69",
"       </td>",
"       <td>",
"        1000 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1500 mg q 18 h",
"       </td>",
"       <td>",
"        1500 mg q 18 h",
"       </td>",
"       <td>",
"        1750 mg q 18 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        70-79",
"       </td>",
"       <td>",
"        1000 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1500 mg q 18 h",
"       </td>",
"       <td>",
"        1500 mg q 18 h",
"       </td>",
"       <td>",
"        1750 mg q 18 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        80-89",
"       </td>",
"       <td>",
"        1000 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 18 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        90-99",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt; = 100",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1000 mg q 12 h",
"       </td>",
"       <td>",
"        1250 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"       <td>",
"        1500 mg q 12 h",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Individualize dose and interval based on serum concentration monitoring (when indicated).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15454=[""].join("\n");
var outline_f15_5_15454=null;
var title_f15_5_15455="Chronic thromboemoli US";
var content_f15_5_15455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic thromboemboli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Echocardiogram in chronic thromboembolic disease demonstrates marked enlargement of the right atrium and right ventricle with septal flattening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_5_15455=[""].join("\n");
var outline_f15_5_15455=null;
